Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
353 "Diabetes mellitus, Type 2"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Reviews
Complications
Article image
Non-Albuminuric Diabetic Kidney Disease: Pathophysiology and Clinical Implications
Eun Roh, Nan Hee Kim
Diabetes Metab J. 2026;50(6):1058-1069.   Published online November 1, 2026
DOI: https://doi.org/10.4093/dmj.2026.1009
  • 554 View
  • 36 Download
AbstractAbstract PDF
Diabetic kidney disease traditionally progresses from glomerular hyperfiltration to albuminuria and kidney function loss. However, many individuals with type 2 diabetes mellitus develop reduced kidney function without increased urinary albumin excretion. This non-albuminuric phenotype accounts for approximately 20%–40% of diabetic kidney disease and 39%–55% of cases with reduced kidney function and is increasingly prevalent. Its emergence may reflect changes in disease biology and clinical management, including renin-angiotensin system blockade, improved cardiovascular risk factor control, and population aging. Histological, imaging, and biomarker studies suggest less prominent classic glomerular injury and greater contributions from intrarenal vascular disease, tubulointerstitial injury, and previous acute kidney injury. Kidney outcomes are generally more favorable than in albuminuric diabetic kidney disease, but associations with mortality remain inconsistent and may be influenced by coexisting cardiovascular disease. Treatment evidence is limited because most landmark kidney outcome trials preferentially enrolled patients with albuminuria, leaving uncertainty about optimal management. This review summarizes evidence on the epidemiology, pathophysiology, clinical characteristics, prognosis, and treatment of non-albuminuric diabetic kidney disease, highlighting its heterogeneity and clinical implications.
Others
Article image
Metabolic Dysfunction-Associated Steatotic Liver Disease: Heterogeneity of Its Pathophysiology and Its Relationship with Type 2 Diabetes Mellitus
Sebastian Schuth, Konstantinos Kantartzis, Andreas L. Birkenfeld, Norbert Stefan
Diabetes Metab J. 2026;50(6):1070-1081.   Published online November 1, 2026
DOI: https://doi.org/10.4093/dmj.2026.0705
  • 515 View
  • 32 Download
AbstractAbstract PDF
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide. People with MASLD can progress to cirrhosis and have an increased risk of developing hepatic decompensation and hepatocellular carcinoma. People with MASLD are also at increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), chronic kidney disease, and extrahepatic cancers and most people with MASLD die from CVD. With a prevalence of about 65%, MASLD is very common among adults with T2DM. This close link between MASLD and cardiometabolic diseases suggests that the conditions share common causes, e.g., insulin resistance, hyperglycaemia, subclinical inflammation, and dysfunctional adipose tissue, and that they also influence each other. In this respect, important insights have been gained in recent years, particularly regarding the heterogeneity of MASLD pathophysiology. In this review we address this heterogeneity and discuss its impact on MASLD-related outcomes. Since successful treatment of MASLD often resembles an effective treatment regimen for T2DM, we discuss how metabolism-based treatment approaches, accounting for the heterogeneity of the pathogenesis of MASLD, might enable personalized treatment of this disease in the future.
Original Articles
Lifestyle and Behavioral Interventions
Effects of a 6-Month Intervention on Body Weight and Cardiometabolic Parameters Based on the Korean Diabetes Prevention Study
Suk Chon, Soo Jin Yun, Hyunji Sang, Sang Youl Rhee, Su Jin Jeong, In Joo Kim, Moon-Kyu Lee, Kyong Soo Park, Kwan-Woo Lee, Bong-Soo Cha, Choon Hee Chung, Tae Sun Park, In-Kyung Jeong, Won-Young Lee, In-Kyu Lee, Sei Hyun Baik, Joong-Yeol Park, Tae Keun Oh, Hyuk-Sang Kwon, Jeong-Taek Woo, the Korean Diabetes Prevention Study Investigators
Diabetes Metab J. 2026;50(6):1213-1228.   Published online November 1, 2026
DOI: https://doi.org/10.4093/dmj.2025.0712
  • 324 View
  • 29 Download
AbstractAbstract PDF
Background
This study evaluated the 6-month effects of the Korean Diabetes Prevention Study (KDPS) interventions on body weight and cardiometabolic parameters in adults with prediabetes.
Methods
Adults aged 30–70 years with body mass index ≥23 kg/m² were randomized to lifestyle modification (LSM), metformin (MET), or standard management (STM). The KDPS-LSM program combined intensive nutrition education and LSM including 10 key healthy habits with personalized counseling, targeting ≥5% weight loss in 6 months followed by long-term maintenance. Cardiometabolic parameters were assessed before and after the intervention (Trial registration: CRIS KCT0002260, NCT02981121).
Results
Of 701 completers (262 STM, 222 LSM, 217 MET), all groups showed significant weight reduction (−0.7 kg STM, −2.3 kg LSM, −2.0 kg MET; P<0.001). The LSM group achieved the largest weight reduction and the highest ≥5% weight-loss rate. Glycemic indices remained largely stable in the LSM and MET groups, whereas FPG increased significantly in the STM group; a significant reduction in HbA1c was observed only in the MET group. Even modest (<5%) weight loss conferred cardiometabolic benefits, and greater loss correlated with higher adherence to LSM or higher MET exposure.
Conclusion
All KDPS interventions reduced body weight after 6 months, with LSM providing the best weight outcomes and MET showing the most favorable glycemic effects.
Basic and Translational Research
Article image
Spatial Transcriptomic Analysis of Human Visceral Adipose Tissue in Different Metabolic Statuses: Methodological Validation and Application
Jisu Jung, Qingzhi Huang, Sumin Lee, Dohoon Kim, Hyunmyeong Oh, Young Suk Park, Hyung Joon Kim, Jung-Kwon Kim, Tae Jung Oh, Amos C. Lee, Joon Ho Moon, Sung Hee Choi
Received October 15, 2025  Accepted January 23, 2026  Published online October 27, 2026  
DOI: https://doi.org/10.4093/dmj.2025.1028    [Epub ahead of print]
  • 4,149 View
  • 128 Download
AbstractAbstract PDFPubReader   ePub   
Background
Adipose tissue consists predominantly of lipid-filled adipocytes with limited cytoplasmic space, posing challenges for spatial transcriptomic analysis. Spatially-resolved laser-activated cell sorting (SLACS) enables precise isolation of tissue sections, offering a strategy to overcome these challenges.
Methods
Human visceral adipose tissue (VAT) samples from lean individuals and those with obesity and type 2 diabetes mellitus (Ob-DM) were analyzed. SLACS was used to isolate perivascular (PV) and adipocyte-rich (AD) areas, followed by full-length RNA sequencing to investigate pathways, cellular composition, and post-transcriptional regulation.
Results
PV and AD areas exhibited distinct transcriptional patterns. Fibro-inflammatory signatures and vascular remodeling pathways were enriched in the PV, while lipid metabolism and antioxidant pathways were predominant in the AD. Cellular deconvolution suggested area- and disease-specific cell composition. Post-transcriptional modifications, including adenosine-to-inosine (A-to-I) RNA editing and isoform switching in metabolic genes were observed in Ob-DM, suggesting that these changes may contribute to adipose dysfunction.
Conclusion
This study demonstrates the technical feasibility of SLACS-based spatial transcriptomic profiling in human VAT, with exploratory biological findings that warrant validation in larger cohorts.
Reviews
Pharmacotherapy
Article image
Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
Ji Yoon Kim, Nam Hoon Kim
Diabetes Metab J. 2026;50(5):844-862.   Published online September 1, 2026
DOI: https://doi.org/10.4093/dmj.2026.0702
  • 5,399 View
  • 215 Download
AbstractAbstract PDFPubReader   ePub   
Incretin-based therapies have transformed the treatment of type 2 diabetes mellitus and obesity by producing a weight-loss magnitude that was previously achievable only through intensive caloric restriction or bariatric surgery. This therapeutic shift has moved the clinical focus from the quantity of weight loss to the quality of weight loss. Lean mass reduction is frequently observed during weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1RAs), dual glucose-dependent insulinotropic polypeptide/GLP-1RAs, or emerging multi-agonists. However, loss of lean body mass does not necessarily indicate equivalent loss of contractile skeletal muscle or sarcopenia. Incretin-based therapy is generally associated with preferential fat mass reduction, relative preservation of lean mass, and potential improvement in muscle quality through reduced myosteatosis. Thus, the clinically relevant question is whether incretin-associated body-composition changes lead to deterioration in muscle strength or physical performance, an increased risk of falls or fractures, or impaired quality of life. Available evidence does not show obvious functional harm; however, long-term data remain limited, especially in people with reduced muscle reserve. A muscle-conscious approach that integrates body-composition assessment, functional monitoring, resistance training, nutritional optimization, and emerging pharmacologic muscle-preserving strategies is needed to achieve high-quality weight loss.
Pathophysiology
Article image
Hypothalamic Inflammaging: A Central Driver of Type 2 Diabetes Mellitus and Metabolic Disease in Aging
Sang Hee Lyoo, Ki Hun Kim, Ki Woo Kim
Diabetes Metab J. 2026;50(5):863-883.   Published online September 1, 2026
DOI: https://doi.org/10.4093/dmj.2026.0599
  • 2,814 View
  • 103 Download
AbstractAbstract PDFPubReader   ePub   
Aging is a major risk factor for type 2 diabetes mellitus (T2DM) and is accompanied by chronic, low-grade inflammation known as inflammaging. Emerging evidence indicates that the hypothalamus, a central regulator of energy and glucose homeostasis, undergoes age-associated inflammatory remodeling that contributes to metabolic dysfunction. In particular, glial cells, including microglia, astrocytes, tanycytes, and neural stem cells, acquire senescence-associated phenotypes characterized by impaired homeostatic functions and increased secretion of pro-inflammatory mediators. These changes disrupt hypothalamic neuronal circuits involved in glucose sensing, energy balance, and insulin responsiveness, thereby potentially promoting systemic insulin resistance and T2DM progression. In this review, we summarize current evidence on the cellular and molecular mechanisms of hypothalamic glial inflammaging and discuss how age-related glial dysfunction may contribute to metabolic abnormalities. We also highlight emerging therapeutic strategies targeting neuroinflammation and glial senescence for the prevention and treatment of age-associated T2DM.
Basic and Translational Research
Article image
Mitochondrial Proteostasis Links Diabetes and Sarcopenia: Cross-Scale Convergence from Experimental Models to Human Multi-Omics
Shibo Wei, Soyeon Shin, Dongryeol Ryu, Chang-Myung Oh
Diabetes Metab J. 2026;50(5):825-843.   Published online September 1, 2026
DOI: https://doi.org/10.4093/dmj.2026.0310
  • 3,543 View
  • 124 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Sarcopenia in type 2 diabetes mellitus is increasingly recognized as a mechanistic consequence of chronic metabolic stress rather than mere age-related comorbidity. This review synthesizes evidence demonstrating how insulin resistance, hyperglycemia, lipotoxicity, and inflammation converge on skeletal muscle mitochondrial proteostasis to drive progressive decline. We evaluate seven pathway modules—mitochondrial dynamics, mitophagy, biogenesis, oxidative phosphorylation, nicotinamide adenine dinucleotide (NAD+)/sirtuin (SIRT)-linked regulation, protein import, and the mitochondrial unfolded protein response (UPRmt)—across an evidence map encompassing basic, clinical, and multi-omics studies. Dynamics and mitophagy represent mechanistically central quality-control nodes; their impairment permits dysfunctional organelle accumulation and promotes atrophic cascades. Direct evidence density, however, remains weighted toward oxidative phosphorylation and mitochondrial biogenesis. NAD+/SIRT-linked regulation, protein import fidelity, and UPRmt represent mechanistically upstream but comparatively underinvestigated signals. We propose a diabetes-centered framework where mitochondrial proteostasis failure mediates atrophy and reinforces insulin resistance via a self-amplifying feed-forward loop, supported by pathway responsiveness to coherent interventions. Human multi-omics data highlight network-level dysregulation rather than isolated defects, underscoring module-based biomarker strategies. Translationally, exercise remains the mechanistic cornerstone, while pathway-directed adjuncts—NAD+ precursor repletion, mitophagy modulators, and emerging pharmacotherapeutics—are warranted for patients with identifiable module-specific failure patterns.
Original Articles
Metabolic Risk/Epidemiology
Article image
Thigh Muscle Quality Predicts the Incidence of Type 2 Diabetes Mellitus
Hun Jee Choe, Steven B. Heymsfield, Michael D. Jensen, Soo Lim
Received December 7, 2025  Accepted March 31, 2026  Published online August 27, 2026  
DOI: https://doi.org/10.4093/dmj.2025.1239    [Epub ahead of print]
  • 1,567 View
  • 42 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Ectopic fat infiltration in skeletal muscle, particularly in the thigh, may impair muscle function and contribute to metabolic dysfunction. However, its predictive value for incident type 2 diabetes mellitus remains understudied.
Methods
We conducted a prospective cohort study of 2,129 East Asian adults (mean age, 57.4±16.9 years; body mass index, 25.0±3.9 kg/m2; 48.5% male) with one or more cardiometabolic risk factors but no diabetes at baseline. Low-density muscle (LDM) area was quantified using non-contrast computed tomography at the midthigh level, with attenuation values of 0–30 Hounsfield units defined as LDM. The association between LDM area and incident diabetes was assessed over a median follow-up of 7.4 years.
Results
During follow-up, 201 males (19.5%) and 156 females (14.1%) developed diabetes. Those who developed diabetes had higher baseline glycosylated hemoglobin levels (6.1%±0.3% vs. 5.7%±0.4%) and larger LDM areas (48.8±14.2 cm2 vs. 38.1±13.2 cm2, both P<0.05). In adjusted Cox models, a large LDM area was independently associated with incident diabetes (hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.52–3.67 for males and HR, 2.15; 95% CI, 1.28–3.61 for females). Incorporating LDM area into models with traditional risk factors improved predictive accuracy (area under the curve increased from 0.810 to 0.838 in males and from 0.893 to 0.908 in females).
Conclusion
LDM area, an indicator of thigh muscle quality and intramuscular fat infiltration, is an independent predictor of incident diabetes.
Basic and Translational Research
Article image
FAM151A Regulates Insulin Secretion in Pancreatic β-Cells and Is Implicated in Pathogenesis of Type 2 Diabetes Mellitus
Jing Zhu, Chenchen Li, Shuaishuai Zhu, Jiawen Wu, Xinyu Zhu, Shixuan Zhuo, Yu Zhang, Zhuoxian Meng, Yan Chen
Received October 22, 2025  Accepted March 5, 2026  Published online August 6, 2026  
DOI: https://doi.org/10.4093/dmj.2025.1061    [Epub ahead of print]
  • 2,535 View
  • 75 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The pathophysiology of type 2 diabetes mellitus (T2DM) is characterized by insulin resistance in peripheral tissues and dysfunction of β-cells. However, the molecular mechanisms underlying β-cell dysfunction remain incompletely understood.
Methods
Analysis of single-cell RNA sequencing of T2DM islets was used to elucidate changes in family with sequence similarity 151 member A (Fam151a) expression. Deletion of Fam151a in INS-1E cells and mice was used to investigate the function of this gene in insulin secretion. Metabolic profiling and metabolomics analyses were used to decipher the effects of FAM151A on metabolic pathways.
Results
Using single-cell RNA sequencing, we identified that Fam151a was significantly downregulated in pancreatic β-cells under T2DM conditions. We next investigated the potential functions of FAM151A in β-cells in vitro and in vivo. FAM151A was localized in the endoplasmic reticulum, and its expression was reduced by high-glucose treatment in INS-1E cells. Genetic deletion of Fam151a in INS-1E cells resulted in proinsulin accumulation, insulin vesicle retention, and impaired insulin secretion. A mouse model with pancreatic β-cell-specific deletion of Fam151a displayed reductions in glucose- and potassium chloride (KCl)-stimulated insulin secretion, and impaired glucose tolerance, without alterations in insulin sensitivity or islet morphology. Integrated metabolic profiling and metabolomics analyses revealed that cellular Fam151a deficiency affects the adenosine triphosphate/adenosine diphosphate ratio, glycolysis, the pentose phosphate pathway, and the purine synthesis pathway.
Conclusion
Our study identifies FAM151A as a key regulator of insulin secretion in β-cells, providing a potential therapeutic target for the management of T2DM.
Pharmacotherapy
Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study
Eun Young Lee, Kyung Ah Han, Soo Heon Kwak, Jun Hwa Hong, You-Cheol Hwang, Gwanpyo Koh, Jing W. Hughes, Soomee Kim, Chang-Seok Lee, Bong-Soo Cha
Received November 13, 2025  Accepted April 20, 2026  Published online July 29, 2026  
DOI: https://doi.org/10.4093/dmj.2025.1152    [Epub ahead of print]
  • 2,913 View
  • 141 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
To evaluate the efficacy and safety of JP-2266, a novel dual sodium-glucose co-transporter 1 (SGLT1)/SGLT2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise.
Methods
In this 12-week, randomized, double-blind, placebo-controlled phase 2 trial, 156 patients with T2DM were randomly assigned (1:1:1) to receive once-daily JP-2266 5 mg (n=51), 10 mg (n=53), or placebo (n=52). The primary endpoint was the change in glycosylated hemoglobin (HbA1c) from baseline to week 12 (ClinicalTrials.gov identifier: NCT06144788).
Results
JP-2266 treatment led to significant, placebo-adjusted reductions in HbA1c of –0.94% (95% confidence interval [CI], –1.24 to –0.65; P<0.0001) for the 5 mg dose and –0.97% (95% CI, –1.26 to –0.68; P<0.0001) for the 10 mg dose. Significant reductions were also observed in fasting plasma glucose (–36.22 mg/dL [95% CI, –47.62 to –24.83] with 5 mg and –39.38 mg/dL [95% CI, –50.71 to –28.05] with 10 mg), and postprandial glucose (–62.30 mg/dL [95% CI, –84.97 to –39.64] with 5 mg and –66.89 mg/dL [95% CI, –89.71 to –44.07] with 10 mg) (all P<0.0001). JP-2266 also reduced body weight of –2.0 to –2.1 kg and systolic blood pressure (–3.6 mm Hg with 10 mg). Improvements in insulin resistance and β-cell function were also observed, as assessed by homeostasis model assessment. Adverse event rates were similar to placebo.
Conclusion
In patients with T2DM inadequately controlled by lifestyle alone, JP-2266 significantly improved glycemic control, reduced body weight and blood pressure, and was well tolerated over 12 weeks. These findings support further investigation of JP-2266 as a potential therapeutic option for T2DM.
Complications
Article image
Cardiorespiratory Fitness and Risk of Microvascular Complications in Patients with Type 2 Diabetes Mellitus
Anning Xu, Haofeng Zhou, Chaofan Wang, Qian He, Ping Wu, Wenjing Wu, Hongjiang Wu, Alice P.S. Kong, Huanyi Cao, Haixia Guan, Yunjiu Cheng
Received November 5, 2025  Accepted February 10, 2026  Published online May 18, 2026  
DOI: https://doi.org/10.4093/dmj.2025.1109    [Epub ahead of print]
  • 3,249 View
  • 65 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study investigated the association between cardiorespiratory fitness (CRF) and the risk of incident microvascular complications in patients with type 2 diabetes mellitus (T2DM), as well as the effects of genetic risk and potential mediation by circulating biomarkers.
Methods
This prospective analysis included 3,102 adults with T2DM from the UK Biobank. CRF was estimated as maximal oxygen uptake using a submaximal cycle test and categorized as low, moderate, or high. Cox proportional hazards models estimated hazard ratios (HRs) for incident diabetic nephropathy, retinopathy, and neuropathy. Interactions with a polygenic risk score and mediating roles of biomarkers were evaluated.
Results
Over a median follow-up of 12.47-years, 331 nephropathy, 268 retinopathy, and 88 neuropathy cases were recorded. Compared to low CRF, moderate and high CRF were associated with a 22% (HR, 0.78; 95% confidence interval [CI], 0.61 to 0.99) and 45% (HR, 0.55; 95% CI, 0.36 to 0.85) lower risk of nephropathy, respectively. Each 1-metabolic equivalent of task increment in CRF was linked to 11% lower nephropathy risk. No significant associations were found for retinopathy or neuropathy. Genetic predisposition did not modify the association between CRF and diabetic nephropathy. Triglycerides and white blood cell count accounted for 7.46% and 12.88% of the association, respectively.
Conclusion
Higher CRF is independently associated with a lower risk of diabetic nephropathy in T2DM, and genetic risk does not alter this relationship. The association is partially mediated by triglycerides and white blood cell count. Assessing CRF may improve risk stratification and prevention of diabetic kidney disease.
Cardiovascular Risk/Epidemiology
Article image
Oxidized Lipoproteins as Independent Predictors of Major Adverse Cardiovascular Events in Type 2 Diabetes Mellitus with Coronary Heart Disease: A Multicenter Prospective Cohort Study
Jun-Xu Gu, Juan Huang, Ai-Min Zhang, Yue Yin, Zi-Wei Wang, Hui-Zhang Bao, Shan-Shan Li, Na Zhang, Li Qin, Zhi-Hong Yue, Kun Wang, Mei Jia, Chun-Yan Wang, Lin Pei, Ming Su
Received October 15, 2025  Accepted February 6, 2026  Published online May 12, 2026  
DOI: https://doi.org/10.4093/dmj.2025.1029    [Epub ahead of print]
  • 3,864 View
  • 53 Download
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Oxidized lipoproteins contribute to atherosclerosis and metabolic dysfunction; however, their prognostic significance for major adverse cardiovascular events (MACEs) in patients with type 2 diabetes mellitus (T2DM) and coexisting coronary heart disease (CHD) remains unclear.
Methods
This multicenter cohort included 3,733 patients with angiographically confirmed T2DM-CHD, followed for 5 years. Baseline circulating oxidized high-density lipoprotein cholesterol (ox-HDL-C), oxidized low-density lipoprotein cholesterol (ox- LDL-C), and oxidized lipoprotein(a) (ox-Lp(a)) were measured, and associations with coronary severity, β-cell function, and MACEs were analyzed using Cox regression, Kaplan-Meier, and restricted cubic spline models.
Results
Patients with MACEs had higher baseline ox-HDL-C, ox-LDL-C, and ox-Lp(a), correlating with greater coronary lesion burden and impaired β-cell function. Restricted cubic spline analyses revealed nonlinear, dose-dependent associations, with MACEs risk increasing above thresholds of 19.88 ng/mL (ox-HDL-C), 25.71 ng/mL (ox-LDL-C), and 19.96 μmol/L (ox-Lp(a)), with sexspecific differences observed. In Cox proportional hazards models, individuals in the highest quartile of oxidized lipoproteins had significantly elevated 5-year MACEs risk compared to those in the lowest quartile, and these associations remained robust after adjusting for confounders (ox-HDL-C: adjust hazard ratio [HR], 1.872; 95% confidence interval [CI], 1.408 to 2.489; P<0.001; ox- LDL-C: adjust HR, 2.239; 95% CI, 1.686 to 2.974; P<0.001; ox-Lp(a): adjust HR, 1.917; 95% CI, 1.442 to 2.549; P<0.001).
Conclusion
Oxidized lipoproteins are independent predictors of MACEs in patients with T2DM-CHD and reflect vascular and metabolic dysfunction. Incorporating oxidized lipoprotein profiling into clinical risk assessment may improve early identification of high-risk individuals and guide preventive strategies.

Citations

Citations to this article as recorded by  
  • Global research trends and hotspots evolution in type 2 diabetes mellitus complicated with coronary heart disease: a bibliometric analysis from 2016 to 2026
    Chunying He, Xiaohua Hu, Xiaolan Yin, Min Zhan, WeiYi Cao, Rui Li
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Reconceptualizing Dyslipidemia: Diversity of Lipid Imbalances and Their Clinical Implications; A Narrative Review
    Ali Mansoursamaei, Amirhossein Yadegar, Fatemeh Mohammadi, Seyed Arsalan Seyedi, Soghra Rabizadeh, Sahar Karimpour Reyhan, Alireza Esteghamati, Manouchehr Nakhjavani
    Health Science Reports.2026;[Epub]     CrossRef
  • Oxidative Stress in Vascular Aging: Therapeutic Potential of the Antioxidant Paradox. A State-of-the-Art Review
    Aleyma Veliz Perez, Mihaela Badea, Sehrish Bilal
    Antioxidants.2026; 15(9): 1152.     CrossRef
Review
Others
Article image
Neutrophil-Linked Inflammatory Mechanisms and Biomarkers in Diabetic Microvascular Complications
Junseo Kim, Daeun Jung, Da Hyun Kang, Hyeongseok Kim, Junyoung O. Park, Jun Young Heo, Seong Eun Lee, Hyun Jin Kim, Ju Hee Lee, Yea Eun Kang, Bon Jeong Ku
Diabetes Metab J. 2026;50(3):450-471.   Published online April 27, 2026
DOI: https://doi.org/10.4093/dmj.2025.1034
  • 6,136 View
  • 151 Download
AbstractAbstract PDFPubReader   ePub   
Diabetic microvascular complications, including nephropathy, retinopathy, and neuropathy, are major causes of morbidity in diabetes. Increasing evidence highlights neutrophils as key contributors to the chronic inflammatory processes underlying these complications. In the diabetic environment, neutrophils exhibit impaired recruitment, defective phagocytosis, dysregulated degranulation, and excessive production of reactive oxygen species and neutrophil extracellular traps (NETs). These dysfunctions not only reduce pathogen clearance but also exacerbate tissue injury through persistent low-grade inflammation. Furthermore, neutrophils interact with other immune cells, such as macrophages, dendritic cells, T cells, and B cells, perpetuating immune imbalance and tissue damage. Various neutrophil-derived cytokines and granular proteins also influence vascular permeability and endothelial dysfunction. In recent years, neutrophil-related biomarkers—such as absolute neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-neutrophil ratio, and systemic immune-inflammation index—have gained attention as accessible and cost-effective tools for predicting and monitoring diabetic microvascular complications. This review summarizes the multifaceted roles of neutrophils in the pathogenesis of diabetic microvascular disease and highlights emerging clinical applications of neutrophil-based inflammatory biomarkers. A better understanding of neutrophil-driven mechanisms may open new avenues for early diagnosis, therapeutic intervention, and personalized care in diabetic patients.
Original Articles
Genetics
Article image
Genetic and Lifestyle Factors Influence High 1-Hour Plasma Glucose, a Predictor of Type 2 Diabetes Mellitus
Soobin Cho, Hyunsuk Lee, Joon Ha, Yeonsoo Park, Joon Ho Moon, Hak Chul Jang, Kyong Soo Park, Nam H. Cho, Michael Bergman, Soo Heon Kwak
Diabetes Metab J. 2026;50(5):1002-1013.   Published online April 22, 2026
DOI: https://doi.org/10.4093/dmj.2025.0362
  • 3,636 View
  • 100 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
High 1-hour plasma glucose (1-h PG) level has been proposed by the International Diabetes Federation to identify high-risk individuals and diagnose type 2 diabetes mellitus (T2DM). In a longitudinal cohort, we examined T2DM risk, β-cell function, and the effects of genetic and lifestyle factors on high 1-h PG.
Methods
We analyzed 7,464 participants without T2D at baseline from a community-based prospective cohort in Korea, who underwent biennial 2-h 75-g oral glucose tolerance tests over 14 years. Incident T2D risk were assessed across 1-h PG groups: < 155, 155–208, and ≥ 209 mg/dL. In 6,588 participants with at least two 1-h PG measurements, we analyzed 1-h PG trajectories by T2D polygenic risk score (PRS; low, 1st quintile; intermediate, 2nd–4th quintiles; high, 5th quintile) and lifestyle, assessed using Life's Essential 8.
Results
Compared to the <155 mg/dL group, hazard ratios for T2DM were 3.34 (95% confidence interval [CI], 2.99 to 3.74; P<0.001) for 155–208 mg/dL, and 6.81 (95% CI, 5.81 to 7.98; P<0.001) for ≥209 mg/dL. Both groups had lower baseline disposition index compared to the <155 mg/dL group (57.3% and 72.7%, respectively; both P<0.001). Higher T2DM PRS was associated with elevated baseline 1-h PG (low: 131 mg/dL, intermediate: 141 mg/dL, high: 151 mg/dL) and faster increase in 1-h PG (1.36 vs. 1.85 vs. 2.21 mg/dL/year; all P<0.001). Importantly, healthy lifestyle attenuated the rate of increase across all PRS groups.
Conclusion
High 1-h PG predicts T2DM risk and is associated with β-cell dysfunction. The 1-h PG level is influenced by genetic risk and can be modified with a healthy lifestyle.
Complications
Article image
Objectively Defined Sleep Regularity Is Associated with Macrovascular and Microvascular Complications among Individuals with Type 2 Diabetes Mellitus: A Cohort Study
Ying Zheng, Manrui Zhang, Hanzhang Wu, Jiahe Wei, Hui-Xin Wang, Torbjörn Åkerstedt, Xiaoyu Li, Xiao Tan
Diabetes Metab J. 2026;50(6):1179-1190.   Published online April 17, 2026
DOI: https://doi.org/10.4093/dmj.2025.0530
  • 3,285 View
  • 67 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We assessed the association of accelerometer-measured sleep regularity with macrovascular and microvascular complications among individuals with type 2 diabetes mellitus (T2DM).
Methods
A total of 3,862 participants with T2DM were included. Sleep regularity metrics measured by wrist-worn accelerometers included the sleep regularity index (SRI) and the standard deviation (SD) of sleep duration. Incident macrovascular complications including coronary heart disease (CHD) and stroke, and microvascular complications including diabetic neuropathy, diabetic kidney disease, and diabetic retinopathy were recorded. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for macrovascular and microvascular complications.
Results
During a median follow-up of 7.2 years, 410 composite macrovascular and 615 composite microvascular events occurred. Compared with regular sleepers (the highest tertile of SRI), irregular sleepers were at higher risk of composite macrovascular complications (HR, 1.29; 95% CI, 1.01 to 1.66) and stroke (HR, 1.97; 95% CI, 1.08 to 3.58). Compared with regular sleepers (the lowest tertile of sleep duration SD), irregular sleepers were at higher risk of composite macrovascular complications (HR, 1.44; 95% CI, 1.12 to 1.84), CHD (HR, 1.40; 95% CI, 1.07 to 1.82), and stroke (HR, 2.07; 95% CI, 1.13 to 3.81). For microvascular complications, no significant associations with sleep regularity metrics were found (all P>0.05). However, dose-response analysis suggested a potential nonlinear association between SRI and diabetic neuropathy, with lower SRI consistently associated with higher risk of diabetic neuropathy (HR, 1.92; 95% CI, 1.28 to 2.88; 5th percentile vs. 50th percentile).
Conclusion
An irregular sleep pattern across days was associated with an increased risk of macrovascular complications and diabetic neuropathy among individuals with T2DM.
Lifestyle and Behavioral Interventions
Article image
Influence of Fibroblast Growth Factor 21 on Delayed Glycemic Improvement Following Acute Exercise in Type 2 Diabetes Mellitus
Ying Zhang, Dan Liu, Yurun Lu, Piao Kang, Xinyu Liu, Qinyi Wang, Anran Chen, Di Cheng, Liang Wu, Qi Li, Xiaolin Wang, Yanli Li, Yaorui Ye, Jingyi Yang, Jiacheng Ni, Qichen Fang, Zhe Huang, Aimin Xu, Weiping Jia, Yong Wang, Guowang Xu, Huating Li
Diabetes Metab J. 2026;50(4):770-784.   Published online March 25, 2026
DOI: https://doi.org/10.4093/dmj.2024.0814
  • 5,249 View
  • 89 Download
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Exercise positively influences glycemic control. Some individuals experience greater glycemic stability on the day after exercise, even without additional physical activity. However, the mechanisms underlying this delayed glycemic improvement remain unclear.
Methods
Seventy-one patients with type 2 diabetes mellitus were assigned to either a 60-minute exercise group or a resting group. Serum fibroblast growth factor 21 (FGF21) levels and untargeted metabolomic profiles were assessed at multiple time points before and after exercise. Interstitial glucose levels were monitored using continuous glucose monitoring system. FGF21 knockout mice and wild-type littermates fed a high-fat diet underwent a 3-week exercise intervention and received FGF21 supplementation.
Results
Individuals exhibiting delayed glycemic improvement (responders) displayed a significantly stronger FGF21 response than non-responders. Baseline metabolites, including p-cresol sulfate and dimethylglycine, differed between responders and non-responders and were associated with the FGF21 response. Longitudinal time-series analyses revealed post-exercise differences in acylcarnitines, fatty acids, and complex lipids between responders and non-responders. Dynamic correlation and mediation analyses supported the role of FGF21 in modulating delayed glycemic improvement through regulation of lipid metabolism. In vivo FGF21 knockout and rescue experiments demonstrated that FGF21 is necessary for these metabolic shifts and the associated improvements in glucose tolerance and insulin sensitivity.
Conclusion
This study suggests that the baseline metabolome is associated with the magnitude of the post-exercise FGF21 response, which influences delayed glycemic improvement through regulation of lipid metabolism pathways.

Citations

Citations to this article as recorded by  
  • Fibroblast Growth Factor 21: Bridging Nutrient Stress Signaling and Exercise-Induced Adaptive Responses
    Dae Ho Lee
    Diabetes & Metabolism Journal.2026; 50(4): 669.     CrossRef
Lifestyle and Behavioral Interventions
Article image
Lifestyle Combination Patterns as Key Modifiable Factors for Type 2 Diabetes Mellitus Risk among Middle-Aged Korean Men
Inji Lee, Hyunjung Lim
Diabetes Metab J. 2026;50(5):990-1001.   Published online March 24, 2026
DOI: https://doi.org/10.4093/dmj.2025.0166
  • 3,322 View
  • 89 Download
AbstractAbstract PDFPubReader   ePub   
Background
The increasing prevalence of type 2 diabetes mellitus (T2DM) worldwide highlights the need to understand risk factors and effective prevention strategies. Although individual lifestyle factors associated with diabetes risk have been identified, research on their collective interactions is limited. This study aimed to identify lifestyle combination patterns in middle-aged Korean men and evaluate their impact on T2DM risk.
Methods
A total of 2,332 middle-aged men without T2DM at baseline (2001–2002) from the Korean Genome and Epidemiology Study (KoGES) cohort were included. T2DM incidence was tracked through the 8th follow-up survey (2017–2018). Lifestyle combination patterns were identified using factor analysis based on sociodemographic, lifestyle, and dietary data. Cox regression was used to assess T2DM incidence across patterns.
Results
Four lifestyle combination patterns were identified: ‘Healthy Lifestyle,’ ‘Low Carb & High Protein,’ ‘High SES & Irregular Lifestyle,’ and ‘Bad Eating Habits.’ The risk of developing T2DM varied across patterns. The ‘Healthy Lifestyle’ and ‘Low Carb & High Protein’ patterns showed a slight decrease in risk in T3, but the differences were not significant. The ‘High SES & Irregular Lifestyle’ pattern was associated with a higher T2DM risk in T3 than in T1 (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.05 to 1.55), but the association was attenuated after adjustment for family history. The ‘Bad Eating Habits’ pattern showed a 1.21-fold higher risk in T3 (HR, 1.21; 95% CI, 1.01 to 1.47).
Conclusion
This study underscores the existence of distinct lifestyle combination patterns and their differential implications for T2DM risk. These findings support the need for tailored preventive strategies based on lifestyle patterns.
Review
Basic and Translational Research
Article image
Redefining β-Cell Function in Type 2 Diabetes Mellitus: From Comprehensive Assessment to Precision Medicine
YongKyung Kim, Joon Ha, Jun Sung Moon
Diabetes Metab J. 2026;50(2):235-252.   Published online March 1, 2026
DOI: https://doi.org/10.4093/dmj.2026.0034
  • 8,150 View
  • 183 Download
  • 3 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   
The global surge in type 2 diabetes mellitus (T2DM) requires a thorough understanding of pancreatic β-cell dysfunction, which remains a central determinant of the disease. However, the evaluation of β-cell insulin secretory capacity is often challenging in clinical practice due to its inherent complexity. This review presents a comprehensive technical overview of diverse assessment methodologies, ranging from conventional fasting-based indices and glucose tolerance tests to advanced mathematical modeling and artificial intelligence-driven approaches. A detailed examination of the methodological strengths and limitations of these various tools is provided to guide their appropriate clinical application. Furthermore, we explore the clinical implications of these assessments in enhancing diagnostic accuracy and tailoring therapeutic strategies. Particular emphasis is placed on the pivotal role of β-cell function evaluation in predicting and achieving diabetes remission—an emerging clinical priority. By integrating the technical landscape of β-cell assessment with practical applications, this review provide a structured framework for optimizing T2DM management and improving long-term patient outcomes.

Citations

Citations to this article as recorded by  
  • Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria
    Sadettin Ozturk, Elif Melis Baloğlu Akyol
    Journal of Clinical Medicine.2026; 15(13): 5049.     CrossRef
  • Short-Term Intensive Insulin Therapy as a Remission Induction Strategy in Newly Diagnosed Type 2 Diabetes Mellitus: A Systematic Review
    Tahira Nasreen, Noor ul huda Awan, Mohammad Uzair, Sunita Kumawat, FNU Vanshika, Esha Sharma, Daniel E Cook, Ghazanfar Ali, Ahmad Sattar
    Cureus.2026;[Epub]     CrossRef
  • Prediction of Six-Month Glycemic Status in Type 2 Diabetes: Development and Internal Validation of a Multivariable Model
    Andreea Diana Igna, Bianca-Lăcrimioara Petca, Paula-Alexandra Popovici, Ioana Moga, Titus David Moga, Timea Claudia Ghitea, Corina Cinezan, Mihaela Simona Popoviciu
    Diagnostics.2026; 16(19): 3201.     CrossRef
  • β‐Cell Recovery Patterns With Initial Combination Versus Stepwise Therapy in Newly Diagnosed Type 2 Diabetes: TRIPLE‐AXEL Post Hoc Analysis
    Il Rae Park, Jun Sung Moon, Joon Ha, Eunvin Ko, Yong‐ho Lee, Ho Chan Cho, Soo Heon Kwak, Soo Lim, Min Kyong Moon, Dong‐Lim Kim, Tae Ho Kim, Sin Gon Kim, Nam Hoon Kim
    Diabetes, Obesity and Metabolism.2026;[Epub]     CrossRef
  • Mitochondria and Pancreatic β-Cells: Central Role in Insulin Secretion and Therapeutic Target for Diabetes
    Allan Langlois, Nadia Benkirane-Jessel, Karim Bouzakri
    Antioxidants.2026; 15(11): 1382.     CrossRef
Original Articles
Lifestyle and Behavioral Interventions
Article image
Association between Changes in Physical Activity and Incident Depression among Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Sangwoo Park, Back Kim, Hye Jun Kim, Sun Jae Park, Jihun Song, Jina Chung, Seogsong Jeong, Sang Min Park, Dae Ho Lee, Soo Jung Choi
Diabetes Metab J. 2026;50(4):785-796.   Published online February 23, 2026
DOI: https://doi.org/10.4093/dmj.2025.0766
  • 3,883 View
  • 96 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study aimed to investigate the relationship between changes in physical activity patterns following a new diagnosis of type 2 diabetes mellitus (T2DM) and the risk of developing depression.
Methods
This study used comprehensive diabetes data from the National Health Insurance Service of South Korea. From this dataset, we included 254,619 individuals newly diagnosed with T2DM between 2009 and 2015 who had health examination data within 2 years before and after their diagnosis date and no prior history of depression. Physical activity levels were quantified using the metabolic equivalent of task (MET) method.
Results
Compared with individuals with 0 MET-min/wk of physical activity before a new T2DM diagnosis, those who increased their activity levels to 500–999 MET-min/wk after diagnosis showed a 23% reduction in the risk of depression, while an increase to ≥1,000 MET-min/wk was associated with a 25% reduction in depression risk. Conversely, individuals with 1–499 MET-min/wk before diagnosis who became inactive after diagnosis experienced a 25% increased risk of depression. A similar trend toward increased depression risk was observed among those who reduced their physical activity from 500–999 or ≥1,000 MET-min/wk.
Conclusion
Changes in physical activity levels before and after a new diagnosis of T2DM significantly influence the risk of developing depression, with increased activity reducing the risk and decreased activity elevating it. This finding underscores the importance of encouraging physical activity to support mental health in patients with newly diagnosed T2DM.
Metabolic Risk/Epidemiology
Article image
Birth Weight, Adult Fat Distribution, and Type 2 Diabetes Mellitus Risk: Sex-Specific Study in a Large Prospective Cohort
Ding Ding, Xiaoyi Luo, Shuhao Chen, Zhilin Liu, Xiaojing Kuang, Tianrui Zhuang, Gaoli She, Hailan Huang, Xingfen Yang, Jie Li, Ran An
Diabetes Metab J. 2026;50(5):977-989.   Published online January 29, 2026
DOI: https://doi.org/10.4093/dmj.2025.0569
  • 3,869 View
  • 122 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Regional fat distribution is a key determinant of metabolic risk, independent of total adiposity. However, the developmental origins of fat depot-specific accumulation and its contribution to type 2 diabetes mellitus (T2DM) remain unclear. We aimed to investigate whether adult fat distribution mediates the association between birth weight (BW) and T2DM risk.
Methods
We analyzed 30,718 diabetes-free UK Biobank participants with magnetic resonance imaging/dual-energy X-ray absorptiometry derived measures of visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue, and gynoid adipose tissue (GAT), liver fat fraction (LFF), pancreatic fat fraction (PFF), and muscle fat infiltration (MFI). Fat depots were adjusted for body mass index (BMI) using sex-specific residuals. Cox regression assessed associations of BW and fat depots with T2DM risk. Mediation analysis assessed indirect effects of fat distribution.
Results
Lower BW was associated with a higher risk of T2DM (hazard ratio per 1 kg increase, 0.71; 95% confidence interval, 0.64 to 0.79), with stronger effects in women. Lower BW was linked to greater VAT, LFF, and PFF, and lower GAT, independent of BMI. Higher levels of VAT, LFF, and PFF were associated with increased T2DM risk, while GAT was protective. Mediation analysis revealed that fat distribution partially mediated the BW-T2DM relationship, with LFF showing the strongest mediation effect (11%). Mediation patterns differed by sex: LFF and VAT were the predominant mediators in women, while LFF and GAT contributed substantially in men.
Conclusion
Fat distribution—particularly liver and visceral fat—partially mediates the BW-T2DM relationship, independent of BMI. These findings highlight the clinical importance of fat depot profiling in understanding the developmental origins of diabetes and guiding early risk stratification.

Citations

Citations to this article as recorded by  
  • Pancreatic fat and the risk of future dysglycemia: a systematic review and meta-analysis
    Jie Yang, Xuan Zhang, Lihong Luo, Zhenjiang Zheng, Chunlu Tan, Xubao Liu, Yonghua Chen
    The Journal of Clinical Endocrinology & Metabolism.2026; 111(10): 2994.     CrossRef
  • Metabolomic signatures and sex-specific associations of prenatal per- and polyfluoroalkyl substances exposure with fetal growth: A meet-in-the-middle and high-dimensional mediation analysis
    Zhen-Hua Li, Cheng-Yang Hu, Xia-Juan Lu, Meng-Na Zhu, Shao-Lei Pu, Rui He, Kai Huang, Mao-Lin Chen, Guo-Peng Gao, Fang-Biao Tao, Xiu-Jun Zhang
    Environment International.2026; 215: 110461.     CrossRef
Complications
Article image
Optimizing Early Detection of Diabetic Kidney Disease through Synergistic Biomarkers and Serum Metabolites in Humans
Xianke Zhou, Yuan Gui, Jia-Jun Liu, Shijia Liu, Dongning Liang, Yuanyuan Wang, Henry Wells Shaffer, Samantha Mae Mallari, Cameron Jones, Priya Gupta, Dier Li, Ke Zhang, Ying Yu, Jianling Tao, Yanlin Wang, Silvia Liu, Dong Zhou, Haiyan Fu
Diabetes Metab J. 2026;50(4):752-769.   Published online January 29, 2026
DOI: https://doi.org/10.4093/dmj.2025.0193
  • 6,005 View
  • 184 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Diabetic kidney disease (DKD) often progresses to end-stage renal disease more rapidly than nondiabetic kidney disease because of persistent hyperglycemia and early activation of multiple pathogenic pathways. Early detection of DKD is crucial for identifying subtle kidney damage before clinical symptoms appear.
Methods
This study combined human serum proteomics with public single-cell RNA sequencing and spatial transcriptomics data from diabetic kidneys to identify key biomarkers for DKD diagnosis. These biomarkers were validated in multiple organs of db/db mice at early and advanced stages. In a discovery cohort, sera from 173 healthy adults and 444 patients with type 2 diabetes mellitus (T2DM), with or without kidney disease, were analyzed using metabolomics and enzyme-linked immunosorbent assay (ELISA). Multiple machine learning algorithms were developed to integrate synergistic biomarkers and serum metabolites for early DKD detection, with results validated in 435 participants from four independent clinical cohorts.
Results
Metalloproteinase-7 (MMP-7) and tenascin C (TNC) were elevated in human diabetic kidneys at the single-cell and spatial levels. Proteomics indicated upregulation of serum amyloid A1 (SAA1) and TNC in the serum of patients with DKD. In db/db mice, all three biomarkers increased in multiple organs by 18 weeks of age. In sera from patients with DKD, MMP-7 and TNC levels were consistently elevated across cohorts. The new algorithms combining MMP-7, SAA1, and TNC enhanced early-stage DKD detection, with approximately 13% improvements in accuracy when serum metabolites were included to distinguish progression from early to advanced DKD stages.
Conclusion
Integrating synergistic biomarkers with serum metabolomics enhances the early detection of DKD, potentially improving outcomes by slowing disease progression in patients with T2DM.

Citations

Citations to this article as recorded by  
  • Recent advances in point-of-care colorimetric biosensors for detecting small molecule metabolites
    Zhiqiang Zhu, Zhun Gu, Xinxing Cao, Shanshan Zhang, Shao Su
    Chemical Communications.2026; 62(48): 12000.     CrossRef
  • Pathology-Anchored Biomarker Research Progress for the Early Diagnosis of Diabetic Kidney Disease: From Pathological Association to Early Validation
    Qiu Li, Mei Yang, Yingyu Luo, Nannan Zhang
    Biomedicines.2026; 14(7): 1643.     CrossRef
  • A hypoxia-derived seven-gene signature reflects immune remodeling in diabetic kidney disease: integrated transcriptomic analysis and experimental validation
    Yue Ji, Jiakun Zhang, Xi Guo, Yunming Xiao, Tieshan Wang, Yifei Zhang, Zhixun Guo, Yuqi Wu, Liangzhen You, Wei Jing Liu
    Diabetes Research and Clinical Practice.2026; 241: 113568.     CrossRef
Guideline/Statement/Fact Sheet
Article image
Health Effects of Sugar-Sweetened and Artificially Sweetened Beverages: Umbrella Review and Evidence-Based Consensus Statement of the Korean Diabetes Association and the Korean Nutrition Society
Jong Han Choi, SuJin Song, Soo Kyoung Kim, Jae Won Cho, Jae Hyun Bae, Shinje Moon, Jeong Hyun Lim, YeonHee Lee, Ji-Yun Hwang, YoonJu Song, Sang Soo Kim
Diabetes Metab J. 2026;50(1):32-46.   Published online January 1, 2026
DOI: https://doi.org/10.4093/dmj.2025.0848
  • 14,736 View
  • 352 Download
  • 7 Web of Science
  • 10 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Excess intake of added sugars contributes to obesity, type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and premature mortality. Sugar-sweetened beverages (SSBs), the main source of added sugars, are consistently linked to adverse outcomes. Artificially sweetened beverages (ASBs) have been suggested as short-term substitutes, but evidence regarding benefits and harms remains inconclusive, and guidance is lacking.
Methods
This consensus statement draws on a structured evidence review combining two approaches: an updated meta-analysis of randomized controlled trials (RCTs) assessing short- to intermediate-term effects of replacing SSBs with ASBs on weight and metabolic outcomes; and an umbrella review of systematic reviews of cohort studies evaluating long-term associations of SSBs and ASBs with major outcomes, including mortality, CVD, and T2DM.
Results
In 14 RCTs (3–76 weeks), replacing SSBs with ASBs produced modest reductions in body weight (–0.73 kg) and body fat (–0.72%), with inconsistent effects on glycemic and cardiometabolic markers. Evidence from 20 systematic reviews of cohorts (up to 34 years follow-up) showed that higher intake of both SSBs and ASBs was associated with increased risks of T2DM, CVD, and mortality, with relative risks for ASBs similar to those for SSBs.
Conclusion
ASBs may serve as a short-term substitution for individuals with high SSB intake, particularly those at elevated metabolic risk. However, regular or long-term use is not recommended due to uncertain safety and potential reinforcement of sweet preference. Public health strategies should emphasize reducing both SSBs and ASBs, prioritizing water and unsweetened beverages as the ultimate goal.

Citations

Citations to this article as recorded by  
  • Do Not Replace Your Sugar, Simply Eat Less!
    Jeehyun Lee, Sunghwan Suh
    Diabetes & Metabolism Journal.2026; 50(1): 30.     CrossRef
  • Diabetes in Bangladesh: The Role of Sugar-Sweetened Beverages
    Mohammad R. Monjur
    Bangladesh Journal of Endocrinology and Metabolism.2026;[Epub]     CrossRef
  • Associations of lifestyle behaviors with overweight and obesity: a cross-sectional study in Shenzhen, China
    Shaojuan Zhao, Leyao Tang, Ni Xiong, Liping Liang, Xin Yin Wu, Chuanning Yu, Xueling Wei, Xuanzhen Wu, Wenjie Dai
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Differential associations of beverage consumption with diabetic retinopathy: a systematic review and dose-response meta-analysis of observational studies
    Siyan Liu, Xuan Wang, Guojun Chao, Wei Lu, Qi Wu, Yuxin Lv, Shuangshuang Yi, Zhengzheng Wu, Jing Yan
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Sugar rationing in the first 1000 days of life and risk of frailty: evidence from a natural experiment
    Rui Zhang, Yuelan Gao, Hong Li, Yuhan Wei, Wanyang Zhong, Kai Tong, Zhibo Sun
    The Journal of nutrition, health and aging.2026; 30(7): 100883.     CrossRef
  • Influencing adolescents' beverage choices: An experimental study on the role of autonomy support and the availability of healthier options
    Roselinde L. van Nee, Ellen van Kleef, Hans C.M. van Trijp
    Appetite.2026; 226: 108618.     CrossRef
  • Factors Influencing Water and Sweet Beverage Purchasing Decisions and Behaviours Among Low-Income Households in Four Peri-Urban Communities in Accra: An Exploratory Study
    Christopher Delali Amegah, Gloria Adobea Odei Obeng-Amoako, Shu Wen Ng, Monica Lambon-Quayefio, Seth Adu-Afarwuah
    International Journal of Environmental Research and Public Health.2026; 23(6): 799.     CrossRef
  • Ten-year trends in sugar-sweetened beverages consumption among Koreans, 2014–2023
    HyunJi Son, Khongorzul Ganbat, SuJin Song
    Nutrition Research and Practice.2026; 20(4): 683.     CrossRef
  • The oral und systemic health risks of sugar consumption: an umbrella review
    J. P. Woelber, N. Wirth, A. Dallmer-Zerbe, C. Tennert
    Clinical Oral Investigations.2026;[Epub]     CrossRef
  • Food-Related Online Media Viewing (Mukbang and Cookbang) and Sugar-Sweetened Beverage and Artificially Sweetened Beverage Consumption Among Korean Adolescents: Using the 2025 Korea Youth Risk Behavior Survey
    Soo Jin Lee, Seol Hwa Park, Cynthia Y. Yoon
    Nutrients.2026; 18(20): 3402.     CrossRef
Pharmacotherapy
Article image
Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial
Yong-ho Lee, Kyung Wan Min, Jun Hwa Hong, Soo Lim, Jae Myung Yu, Choon Hee Chung, Jun Sung Moon, Jong Chul Won, Chul Woo Ahn, Jie-Eun Lee, Tae Nyun Kim, Byung-Wan Lee
Diabetes Metab J. 2026;50(3):576-586.   Published online December 19, 2025
DOI: https://doi.org/10.4093/dmj.2025.0528
  • 6,533 View
  • 157 Download
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study assessed the efficacy and safety of HD-6277, a novel oral G protein-coupled receptor 40 (GPR40) agonist in adults with inadequate control of type 2 diabetes mellitus (T2DM).
Methods
This double-blind, randomized, placebo-controlled phase 2 trial recruited 112 individuals aged 18–75 years with T2DM and glycosylated hemoglobin (HbA1c) levels between 7.0% and 10.0% while on diet and exercise alone for at least 8 weeks before screening. Parallel-group randomized trials of HD-6277 (50 and 100 mg groups vs. placebo) were conducted for 12 weeks. The primary outcome was the change in HbA1c levels from baseline to week 12. Secondary outcomes included changes in HbA1c, fasting plasma glucose (FPG), postprandial glucose, insulin, glycoalbumin, and C-peptide at weeks 4, 8, and 12.
Results
At week 12, HD-6277 at 50 and 100 mg demonstrated statistically significant reductions in HbA1c compared to placebo, with least square (LS) mean differences of –0.73% (95% confidence interval [CI], –1.11 to –0.35; P=0.0002) and –0.85% (95% CI, –1.21 to –0.50; P<0.0001), respectively. Both doses also produced clinically meaningful reductions in FPG. Additionally, HD- 6277 at 100 mg significantly increased the insulinogenic index compared to placebo, with an LS mean difference of 1.91 (95% CI, 0.34 to 3.48; P=0.0175). No clinically relevant treatment-related adverse events were observed.
Conclusion
HD-6277 at 50 and 100 mg improved glycemic control and was well-tolerated in adults with T2DM inadequately managed with diet and exercise. GPR40 agonists may offer a promising new therapeutic option for T2DM.

Citations

Citations to this article as recorded by  
  • Revisiting GPR40 Agonist in Type 2 Diabetes Mellitus: A Cautious but Meaningful Return
    Eun-Hee Cho
    Diabetes & Metabolism Journal.2026; 50(3): 472.     CrossRef
  • Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains
    Yohan Seo, Joohan Woo
    Drug Discovery Today.2026; 31(6): 104843.     CrossRef
Pharmacotherapy
Article image
Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs
Jun Hwa Hong, Kyung Wan Min, Chang Beom Lee, Parinya Chamnan, Thanitha Sirirak, Kiran Sony, Sarinya Sattanon, Hae Jin Kim, Sang-Yong Kim, Younghee Kim, Jung A Heo, Jae Min Cho, Jae Jin Nah, Mi Hee Park, Jae Hyeon Kim
Diabetes Metab J. 2026;50(5):952-964.   Published online December 15, 2025
DOI: https://doi.org/10.4093/dmj.2025.0477
  • 7,227 View
  • 235 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The study evaluated the efficacy and safety of enavogliflozin, a novel, promising selective sodium-glucose cotransporter 2 inhibitor, as an add-on in adults with type 2 diabetes mellitus (T2DM) inadequately controlled with insulin alone or combined with other antidiabetic drugs (OADs).
Methods
The double-blind, placebo-controlled, multicenter trial was conducted in South Korea and Thailand. Individuals with glycosylated hemoglobin (HbA1c) ≥7.5% after ≥8-week treatment with background insulin alone or combined with ≤2 OADs were randomized to receive enavogliflozin 0.3 mg or placebo (n=120 each) for 24 weeks. The primary outcome was a change in HbA1c at week 24. Secondary outcomes included, among others, changes in body weight, blood pressure, and other measures of glycemic control. Adverse events (AEs) were investigated throughout the study (Clinical trial registration number: NCT05466643).
Results
At week 24, the placebo-adjusted mean change in HbA1c from baseline in the enavogliflozin group was –0.9% (P<0.001). Also, placebo-adjusted mean changes in fasting plasma glucose (–32.4 mg/dL, P<0.001), body weight (–1.3 kg, P<0.001), and total daily dose of insulin (–1.3 units, P=0.010) at week 24 were statistically significant. In addition, a significant decrease in blood pressure and fasting C-peptide was observed in the enavogliflozin group, along with a significant increase in homeostasis model assessment of β-cell function, yet without a concomitant change in homeostasis model assessment of insulinresistance. No significant increase in treatment-related AEs was observed for enavogliflozin.
Conclusion
Enavogliflozin 0.3 mg/day is an efficacious and safe add-on treatment option in T2DM patients controlled inadequately with insulin alone or combined with OADs.

Citations

Citations to this article as recorded by  
  • Insulin Intensification and Simplification Strategies in Patients with Type 2 Diabetes and Overweight or Obesity: A Scoping Review
    Chew Huey Chua, Wei Lim Chong, Hasniza Zaman Huri
    International Journal of Molecular Sciences.2026; 27(20): 9050.     CrossRef
Genetics
Article image
Evaluation of Sex-Stratified Polygenic Risk Scores for Type 2 Diabetes Mellitus and Glycemic Traits in the Framingham Heart Study
Ningyuan Wang, Yixin Zhang, Philip Schroeder, Alicia Huerta-Chagoya, Ravi Mandla, James B. Meigs, Alisa K. Manning, Ching-Ti Liu, Josée Dupuis, Josep M. Mercader
Diabetes Metab J. 2026;50(4):797-807.   Published online December 9, 2025
DOI: https://doi.org/10.4093/dmj.2025.0557
  • 3,989 View
  • 59 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Diabetes is a multifactorial disease with significant genetic predisposition. Polygenic risk scores (PRS) have been developed to estimate an individual’s genetic risk of a disease. Traditionally, PRS utilize sex-combined genome-wide association studies (GWAS) due to the limited availability of sex-stratified summary statistics. This study explores sex-dimorphic genetic effects and evaluates the potential benefits of incorporating sex-stratified effects in PRS for type 2 diabetes mellitus (T2DM) and glycemic traits by comparing PRS performance derived from sex-combined versus sex-stratified GWAS.
Methods
We performed a sex-heterogeneity test across sex-specific GWAS and identified nine signals with sex-dimorphic effects for T2DM. PRS[sex-combined] and PRS[sex-stratified] were developed using sex-combined and sex-stratified GWAS results for T2DM (41,444 cases and 354,539 controls), fasting glucose (n=120,595) and fasting insulin (n=98,210). We evaluated these PRS models in 8,379 participants (1,303 cases and 7,076 controls) from the Framingham Heart Study not included in the PRS derivation.
Results
Our findings suggest that sex-combined PRS currently offer better predictive performance for T2DM and glycemic traits.
Conclusion
These results highlight the need for larger sex-stratified studies and the optimization of sex-stratified risk models for clinical practice.

Citations

Citations to this article as recorded by  
  • Global burden of type 2 diabetes attributable to dietary risks in working-age adults aged 25–64 years: insights from the GBD 2023 study
    Xin Chen, Xiyue Xiong, Lawrence W.C. Chan, Changtao Hu, Sheng Li, Sijun Yang
    Diabetes Research and Clinical Practice.2026; 240: 113521.     CrossRef
  • The insulin gene in humans and mice: evolution, regulation, and sex-specific mechanisms of diabetes susceptibility
    Ali Mazloum, Nikita Batashkov, Veronika Ledyaeva, Gava Khulkhachiev, Dmitry Tabakov, Olga N. Mityaeva, Pavel Yu Volchkov
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
Lifestyle and Behavioral Interventions
Article image
Risk Determinants of Type 2 Diabetes Mellitus with Severe Obesity and Prediction Model for Diabetes Remission after Bariatric Metabolic Surgery
Zilong Wu, Yuxia Li, Dehui Wang, Bing Wu, Kaisheng Yuan, Yun Liu, Hao Zhu, Sijie Chen, Wah Yang, Ruixiang Hu, Cunchuan Wang
Diabetes Metab J. 2026;50(2):368-384.   Published online November 25, 2025
DOI: https://doi.org/10.4093/dmj.2025.0337
  • 4,936 View
  • 143 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Bariatric metabolic surgery (BMS) has been established as an effective intervention for obesity and type 2 diabetes mellitus (T2DM). However, systematic research addressing the onset of diabetes and post-surgical remission in severely obese populations remains scarce. This study aims to identify risk factors for T2DM in populations with severe obesity undergoing BMS and develop and validate a prediction model for the primary outcome of diabetes remission (DR) 1 year after BMS. This research provides a precise tool for managing T2DM in populations with severe obesity.
Methods
This research utilizes the China Obesity and Metabolic Surgery Database, retrospectively analyzing 3,670 severely obese populations who underwent BMS between January 2014 and January 2024. Differential analysis identified risk factors for T2DM onset, while univariate and multivariate regression analyses identified independent risk factors for DR post-surgery. A prediction model for DR was developed and internally validated.
Results
Factors associated with T2DM onset in severely obese populations included family history of diabetes, hypertension, hyperlipidemia, glycosylated hemoglobin (HbA1c) levels, and fasting plasma glucose. Independent factors influencing DR postsurgery included diabetes duration, surgical method, HbA1c, and insulin requirement. Subsequent model validation confirmed stable performance metrics (area under the curve values training, 0.71; validation, 0.72).
Conclusion
This study identifies risk factors for T2DM onset and a prediction model for DR following BMS in the Chinese severely obese population. It provides a more precise risk assessment tool for patients with severe obesity and T2DM, and lays the groundwork for future multicenter studies and international collaborations.

Citations

Citations to this article as recorded by  
  • Validation Performance of Screening Tools for Predicting Obstructive Sleep Apnea Among Chinese Patients Undergoing Metabolic Bariatric Surgery: Insights from a Multicenter Database
    Lizhen Liu, Pei Tang, Joyce Wai-Ting Chiu, Zhiyong Dong, Cunchuan Wang, Weixin Huang, Wenhui Chen
    Obesity Surgery.2026; 36(6): 3117.     CrossRef
  • Explainable Machine-Learning Model for Predicting Severe Obstructive Sleep Apnea in Patients Undergoing Metabolic Bariatric Surgery
    Wenhui Chen, Lili Li, Junsen Peng, Cunchuan Wang, Guie Gao, Zhiyong Dong
    Obesity Surgery.2026; 36(8): 4334.     CrossRef
Pharmacotherapy
Article image
Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus
Inha Jung, Hangseok Choi, In Young Choi, Hyun Joo Cho, So Young Park, Da Young Lee, Ji A Seo, Nan Hee Kim, Ji Hee Yu
Diabetes Metab J. 2026;50(3):565-575.   Published online November 24, 2025
DOI: https://doi.org/10.4093/dmj.2025.0681
  • 4,288 View
  • 87 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic control through insulinotropic and anorectic effects. However, the role of adipokines and appetite-related hormones in mediating the glycemic response remains unclear. This study evaluated changes in abdominal fat, food cravings, and circulating adipokines and gut hormones following dulaglutide treatment and identified predictors of glycemic improvement in type 2 diabetes mellitus (T2DM).
Methods
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly. Abdominal computed tomography, the General Food Cravings Questionnaire-Trait, and fasting levels of leptin, adiponectin, obestatin, ghrelin, and resistin were assessed at baseline and week 24. Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks. Multivariable regression analysis was performed to identify the factors associated with glycemic improvement.
Results
Among the 67 patients who completed the study, dulaglutide significantly reduced HbA1c, food cravings, leptin, and adiponectin levels. Obestatin levels increased modestly. Responders showed greater improvement in β-cell function and more pronounced reductions in food cravings. In the adjusted models, a decrease in leptin and an increase in obestatin were independently associated with HbA1c reduction, while decreased adiponectin was associated with poorer glycemic outcomes. Changes in body mass index or abdominal fat were not associated with glycemic improvement.
Conclusion
Dulaglutide improved glycemic control through mechanisms beyond weight reduction. Hormonal changes in leptin, adiponectin, and obestatin may help predict responses to GLP-1 RAs therapy.

Citations

Citations to this article as recorded by  
  • Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study
    Inga C. Brouer, Aida Zani, Henning Olbrich, Ralf J. Ludwig, Diamant Thaçi
    Frontiers in Medicine.2026;[Epub]     CrossRef
Basic and Translational Research
Article image
Targeting PGC-1α by miRNA-374 Simultaneously Improve β-Cell Dysfunction and Suppress Hepatic Glucose Overproduction
Ji-Won Kim, Joonyub Lee, Young-Hye You, Chan-Hee Oh, Heon-Seok Park, Eun Young Lee, Seung-Hwan Lee, Seung-Hyun Ko, Ji-Ho Park, Kun-Ho Yoon
Diabetes Metab J. 2026;50(3):535-551.   Published online November 3, 2025
DOI: https://doi.org/10.4093/dmj.2025.0287
  • 6,098 View
  • 110 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
In this study, we aimed to validate the potential of miR-374 in ameliorating hyperglycemia by regulating peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1α) expression in pancreatic islets and liver.
Methods
To identify miRNAs targeting PGC-1α, we performed miRNA chip analysis in rat islets under hyperglycemic and euglycemic conditions. Luciferase reporter assay was performed to identify miR binding sites in the 3’-untranslated region (3’ UTR) of PGC-1α. In db/db mice, miRNA-encapsulated adenoviruses were administered and intraperitoneal glucose tolerance test and glucose stimulated insulin secretion tests were performed. For enhanced delivery to β-cells, we developed exendin-4 (Ex-4) coated cationic lipoparticles (CCLs) encapsulating miRNAs. The therapeutic potential of Ex-4-CCL-miRNA was further evaluated in insulin-producing cells derived from induced pluripotent stem cells.
Results
By analyzing miRNA expression in primary rat islets exposed under hyperglycemic environment, we identified miR-374 as a potential target. In vitro experiments confirmed that miR-374 significantly suppressed PGC-1α expression in β-cells and hepatocytes by binding to its 3’-UTR. In vivo experiments using adenovirus-mediated miR-374 (Ad-miR-374) delivering directly to the pancreas and liver of db/db mice demonstrated improved glycemic control, enhanced insulin secretion, and downregulated hepatic gluconeogenesis-related genes (G6Pase, Pepck, PC). To enhance the clinical applicability of miR-374, we developed Ex-4-CCLs. Ex-4-CCL-miR-374 successfully alleviated hyperglycemia, restored pancreatic islet function, and decreased gluconeogenesis gene expression in db/db mice. Furthermore, Ex-4-CCL-miR-374 improved insulin secretory function in glucotoxicity-exposed human induced pluripotent stem cell-derived insulin producing cells.
Conclusion
Based on these findings, we propose that Ex-4-CCL-miR-374 as a promising therapeutic approach to reverse β-cell dysfunction and improve hepatic insulin resistance in type 2 diabetes mellitus.

Citations

Citations to this article as recorded by  
  • β‐cell recovery revisited: Is prediabetes remission driven by insulin sensitivity or β‐cell function?
    Joonyub Lee, Kun‐Ho Yoon
    Journal of Diabetes Investigation.2026; 17(5): 716.     CrossRef
Genetics
Article image
Elucidating the Epigenetic Landscape of Type 2 Diabetes Mellitus: A Multi-Omics Analysis Revealing Novel CpG Sites and Their Association with Cardiometabolic Traits
Ren-Hua Chung, Chun-Chao Wang, Djeane Debora Onthoni, Ben-Yang Liao, Tzu-Sheng Hsu, Eden R. Martin, Chao A. Hsiung, Wayne Huey-Herng Sheu, Hung-Yi Chiou
Diabetes Metab J. 2026;50(1):153-164.   Published online October 28, 2025
DOI: https://doi.org/10.4093/dmj.2025.0041
  • 12,240 View
  • 120 Download
  • 2 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Type 2 diabetes mellitus (T2DM) is a complex, multifactorial disease with a significant global burden. Although genome-wide association studies (GWAS) have identified many T2DM-associated variants, most lie in non-coding regions, making it difficult to interpret their functional roles.
Methods
We aimed to identify genetically regulated Cytosine–phosphate–Guanine (CpG) sites associated with T2DM by conducting a methylome-wide association study (MWAS), followed by Mendelian randomization (MR) and functional validation using human pancreatic cells and mouse models. MWAS was performed using summary statistics from large-scale GWAS and a DNA methylation (DNAm) prediction model to test associations between genetically predicted DNAm and T2DM.
Results
We identified 111 CpG sites significantly associated with T2DM in Europeans, including 8 novel sites near genes not previously linked to T2DM. These findings were replicated in independent datasets. Many CpGs also showed associations with cardiometabolic traits, highlighting shared epigenetic mechanisms. Trans-ethnic MR analysis confirmed consistent effects for six CpGs in East Asians. Functional analysis revealed that several CpGs regulate gene expression in human pancreatic α- and β-cells. Among them, 2´-5´-oligoadenylate synthetase like (OASL) expression, regulated by a significant CpG, was differentially expressed in α-cells of T2DM cases compared to controls. Supporting evidence from mouse models suggests a role for OASL in glucose regulation.
Conclusion
Our study identifies novel genetically regulated CpG sites associated with T2DM risk and highlights OASL as a potential epigenetic regulator of glucose metabolism in α-cells. These findings provide mechanistic insights into the epigenetic architecture of T2DM and suggest potential targets for cross-ethnic biomarker development and therapeutic intervention.

Citations

Citations to this article as recorded by  
  • Emerging molecular roles of oligoadenylate synthetase-like protein (OASL) in liver fibrosis: Linking antiviral immunity, inflammation, and fibrotic remodeling
    Mwense Leya, Thach Phan Van, Yoon-Seok Roh, Bumseok Kim
    The International Journal of Biochemistry & Cell Biology.2027; 202: 107069.     CrossRef
  • Unravelling the molecular mechanisms causal to type 2 diabetes across global populations and disease-relevant tissues
    Ozvan Bocher, Ana Luiza Arruda, Satoshi Yoshiji, Chi Zhao, Alicia Huerta-Chagoya, Chen-Yang Su, Xianyong Yin, Davis Cammann, Henry J. Taylor, Jingchun Chen, Ken Suzuki, Ravi Mandla, Ta-Yu Yang, Fumihiko Matsuda, Josep M. Mercader, Jason Flannick, James B.
    Nature Metabolism.2026; 8(2): 506.     CrossRef
  • Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer
    Chun-Chao Wang, Sabareeswaran Krishnan, Yen-Hsun Wang, Kai-Chen Hsu, Tzu-Sheng Hsu, Chung-Hsing Chen, Shang-Hung Chen, Ren-Hua Chung
    npj Breast Cancer.2026;[Epub]     CrossRef
Pharmacotherapy
Article image
Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
Jun Hwa Hong, Kyung Ah Han, You-Cheol Hwang, Eun-Gyoung Hong, Hae Jin Kim, Chang Beom Lee, Ho Chan Cho, Jong Chul Won, Hun-Sung Kim, Eui-Hyun Kim, Gwanpyo Koh, Kwang Hyun Ahn, Kyong Soo Park
Diabetes Metab J. 2026;50(2):320-330.   Published online October 28, 2025
DOI: https://doi.org/10.4093/dmj.2024.0696
  • 16,283 View
  • 257 Download
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study investigated the efficacy and safety of pioglitazone 30 mg/day add-on to inadequately controlled type 2 diabetes mellitus (T2DM) patients with treatment of dapagliflozin and metformin.
Methods
In this multicenter (34 sites), double-blind, randomized, phase 3 study, patients with T2DM with an inadequately controlled glycosylated hemoglobin (HbA1c) over 7.0% to treatment with dapagliflozin (10 mg/day) and metformin (≥1,000 mg/day) were randomized to receive additional pioglitazone 30 mg/day (n=124) or placebo (n=122) for 24 weeks. The primary outcome was the mean change of HbA1c from baseline to 24 weeks treatment. The efficacy and safety were evaluated with open label extension period, switching placebo to pioglitazone 30 mg/day at 48 weeks (ClinicalTrials.gov identifier: NCT05296044).
Results
The HbA1c after 24 weeks treatment reduced from 7.8%±0.8% to 7.0%±0.6% (P<0.0001). The proportions of patients who achieved HbA1c less than 7.0% at 24 weeks were significantly higher in pioglitazone add-on group (51.61% in pioglitazone vs. 22.95% in placebo, P<0.0001), or less than 6.5% at 24 weeks (21.77% in pioglitazone vs. 2.46% in placebo, P<0.0001). Body weight gain was 2.0 kg at 24 weeks with pioglitazone 30 mg/day and –0.6 kg at 24 weeks with placebo.
Conclusion
Addition of pioglitazone 30 mg/day to T2DM patients who did not reach the target HbA1c (≤7%) with treatment of dapagliflozin 10 mg/day and metformin over 1,000 mg/day showed effective glucose lowering efficacy without significant hypoglycemia and good tolerability with low prevalence of edema in spite of modest weight gain.

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Pioglitazone Added to Metformin and SGLT2 Inhibitors in Type 2 Diabetes: An Updated Systematic Review and Meta-analysis
    Syed Ibad Hussain, Amna Amir Jalal, Zahabia Adnan, Shanza Shakir, Devya Khaim Chandani, Muhammad Ali Makhdoom
    Annals of Pharmacotherapy.2026;[Epub]     CrossRef
  • Bioequivalence of Fixed-Dose Dapagliflozin-Pioglitazone in Healthy Indian Adults: Results From the Randomized Crossover PRO-4 Study
    J. Hari Prasath, Umesh Garg, Kalyan Kurapati, Abhamoni Baro Agarwal, Parul Singhal, Thamburaj Anthuvan, Smriti Gadia, Amit Gupta, Sridhar S B.
    Cureus.2026;[Epub]     CrossRef
  • PPARγ: a transfactor for Th-cell subsets
    Sihang Chen, Ming Chu
    Frontiers in Immunology.2026;[Epub]     CrossRef
Cardiovascular Risk/Epidemiology
Article image
Prognostic Impact of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Coronary Ischemia: A Retrospective Cohort Study
Haochen Xuan, Yik-Ming Hung, Ran Guo, Qingwen Ren, Jiayi Huang, Jingnan Zhang, Wenli Gu, Ho-Leung Chan, Gaozhen Cao, Run Wang, Calvin Ka-Lam Leung, Tongda Xu, Kai-Hang Yiu
Diabetes Metab J. 2026;50(3):599-611.   Published online October 24, 2025
DOI: https://doi.org/10.4093/dmj.2025.0200
Correction in: Diabetes Metab J 2026;50(6):1241
  • 11,095 View
  • 171 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Patients with type 2 diabetes mellitus (T2DM) and coronary ischemia face an exceptionally elevated risk, and the achievement of complete revascularization (CR) within this population could be challenging.
Methods
Patients with T2DM and coronary ischemia based on coronary angiography and retrospective angiographic fractional flow reserve analysis between 2014 and 2016 were included. The impact of the extent of revascularization on the improvement of endpoint events by sodium-glucose cotransporter 2 (SGLT2) inhibitors was analyzed. The primary study endpoint was major adverse cardiac events (MACE), while all-cause mortality served as secondary endpoints. Kaplan-Meier analysis and Cox proportional hazards regression model were adopted to assess the association between SGLT2 inhibitors and endpoint incidence.
Results
A total of 671 patients were identified. Among them, 206 (30.7%) were prescribed with SGLT2 inhibitors, while 484 (72.1%) achieved CR after the operation. During a mean 36-month follow-up, 100 MACE and 89 all-cause mortality were recorded. SGLT2 inhibitor users demonstrated lower rates of MACE (8.3% vs. 17.8%, P=0.002) and all-cause mortality (6.3% vs. 16.3%, P<0.001) compared to non-users. After adjusting for confounding factors in multivariable Cox analysis, the association between SGLT2 inhibitors and reduced MACE incidence remained consistent both in the CR and incomplete revascularization subgroups (hazard ratio [HR], 0.498; 95% confidence interval [CI], 0.246 to 0.938; P=0.040; and HR, 0.341; 95% CI, 0.123 to 0.805; P=0.023, respectively).
Conclusion
SGLT2 inhibitors were found to be associated with a reduced risk of 3-year MACE and all-cause mortality in patients with T2DM and coronary ischemia, regardless of extent of revascularization.
Reviews
Lifestyle and Behavioral Interventions
Article image
Clinically Practical and Affordable Lifestyle Modification to Prevent Diabetes Mellitus in Real Practice
Inji Lee, Minji Kang, Ji Hye Choi, Hyunjung Lim, Suk Chon
Diabetes Metab J. 2025;49(5):951-963.   Published online September 1, 2025
DOI: https://doi.org/10.4093/dmj.2025.0675
  • 10,798 View
  • 278 Download
  • 2 Web of Science
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
As the prevalence of type 2 diabetes mellitus continues to rise, the development of effective and sustainable prevention strategies has become a critical public health priority. Evidence from large-scale randomized controlled trials has established that lifestyle modification (LSM) programs can substantially reduce the risk of diabetes in high-risk individuals. However, routine implementation is limited by high intensity, costs, and resource requirements. We summarize major prevention trials and their effectiveness, feasibility, and limitations. Building on these insights, we introduce the Korean Diabetes Prevention Study (KDPS) as a contextually tailored model for the Korean healthcare system. The KDPS-LSM program was designed to integrate cultural and clinical relevance with practical applicability, consisting of a 6-month intensive phase of structured nutrition and lifestyle education followed by a maintenance phase to support long-term adherence. To promote sustainable change, the program incorporates the ‘10 habit’ lifestyle messages, grounded in the transtheoretical model of behavior change, which are designed for easy implementation in daily life. This review underscores the importance of developing culturally appropriate LSM programs that balance effectiveness with feasibility, and suggests that the KDPS-LSM model could serve as a useful foundation for establishing practical diabetes prevention strategies within national healthcare systems.

Citations

Citations to this article as recorded by  
  • The Triangular Interaction Between Dietary Polyphenols, Gut Microbiota and Type 2 Diabetes
    Emily Bayliss, Landri Shope, Seth Woodfin, Gretchka Mair, Matthew H. Becker, William Moore
    International Journal of Molecular Sciences.2026; 27(11): 4782.     CrossRef
Lifestyle and Behavioral Interventions
Article image
Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions
Matthew J. Savage, Jonathan Goldney, Tommy Slater, Priscilla Sarkar, Jack A. Sargeant, Emma G. Wilmot, Melanie J. Davies
Diabetes Metab J. 2025;49(5):934-950.   Published online September 1, 2025
DOI: https://doi.org/10.4093/dmj.2025.0561
  • 13,336 View
  • 411 Download
  • 7 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   ePub   
The global prevalence of early-onset type 2 diabetes (EOT2D) is rising rapidly. Adults with EOT2D represent a high-risk population characterised by increased rates of microvascular and macrovascular complications, adverse psychological wellbeing and psychiatric comorbidities such as depression, and premature mortality compared to those with later-onset type 2 diabetes mellitus. This emerging population faces unique challenges, including high levels of diabetes-related stigma, clinical inertia, and competing life demands, such as starting a family. This review synthesises current evidence on the clinical management of EOT2D. Key therapeutic targets include weight reduction, preservation of β-cell function, cardiometabolic risk management, and psychological support. Overall, there are few randomized controlled trials (RCTs) undertaken specifically in adults with EOT2D. However, we summarise early data from the few RCTs that do report outcomes specific in young adults, with bariatric surgery, tirzepatide and intensive lifestyle interventions emerging as particularly effective treatments. There is a strong rationale that technology-based inventions and structured education programs may prove to be effective treatments but data from RCTs is lacking. We provide broad recommendations for future research and clinical practice based on the current evidence. In conclusion, substantial further research is required to inform tailored, evidence-based guidelines and improve long-term outcomes in this underserved population.

Citations

Citations to this article as recorded by  
  • Identification of oral microbial biomarkers for prediabetes in young adults: A two-stage population-based study
    Jiaqi Li, Guishao Tang, Zhiguo Xie, Lin Yang, Zhiguang Zhou, Keyu Guo
    Diabetes Research and Clinical Practice.2026; 232: 113101.     CrossRef
  • Redefining β-Cell Function in Type 2 Diabetes Mellitus: From Comprehensive Assessment to Precision Medicine
    YongKyung Kim, Joon Ha, Jun Sung Moon
    Diabetes & Metabolism Journal.2026; 50(2): 235.     CrossRef
  • Correlation between TyG index, TyG-BMI index and AIP index and early-onset type 2 diabetic nephropathy
    Xiangyan Wei, Baolan Liang, Airong Chen
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials
    Francesco Zaccardi, Vanita R. Aroda, Ecenur Guder Arslan, Lars Bardtrum, Jonathan Goldney, Erik Ising, Prachi Priyadarshini, Tommy Slater, Melanie J. Davies
    Diabetes, Obesity and Metabolism.2026; 28(7): 5787.     CrossRef
  • Evaluation of a secondary care multidisciplinary clinic for adults with early‐onset type 2 diabetes at high risk in Leicester, Leicestershire and Rutland
    Jonathan Goldney, Malak Hamza, Priscilla Sarkar, Harriet Morgan, Nicole Green, James Ridgeway, Victoria Alabraba, Laura Willcocks, Krupali Chandracant, Kashmala Javed, Rhys O'Callaghan, Finley Turner, Samuel Seidu, Claire L. Meek, Melanie J. Davies
    Diabetic Medicine.2026;[Epub]     CrossRef
  • Psychosocial care and experiences in young adults living with early‐onset type 2 diabetes: A narrative review
    Molly Caba, Márcia Carvalho, Angus Forbes, Rita Forde, Kirandip Gill, Mohsin Khalifa, Judith Parsons, Jane Speight, Paula M. Trief, Michelle Hadjiconstantinou
    Diabetic Medicine.2026;[Epub]     CrossRef
  • Digital Management of Early-Onset Type 2 Diabetes: Empowerment, Challenges, and Future Outlook
    Li-Jun Guo, Kah-Seng Low, Sok-Kun Tae, Lee-Ling Lim
    Current Diabetes Reports.2026;[Epub]     CrossRef
  • Comparison of the Efficacy of Once Weekly Dose of Trelagliptin Versus Once Daily Dose of Vildagliptin on the Levels of HbA1c in Type-2 Diabetes Patients
    Bilal Hussain, Ehsan Ullah, Farah Sadiq, Junaid Mustafa, Nashmia Babar, Muhammad Irfan Jamil
    Pakistan Journal of Health Sciences.2026; : 85.     CrossRef
  • Global Trends and Exposure Profiling of Early‐Onset Type 2 Diabetes: An Ecological Analysis Using Machine Learning
    Wude Guo, Yang Liu, Jing Wang, Yi Ma, Jiaxin Chen, Chengyao Sun, Guoxiang Liu
    Diabetes, Obesity and Metabolism.2026;[Epub]     CrossRef
Original Articles
Others
Article image
The Concurrent Challenges of Sarcopenia and Frailty: A 5-Year Mortality Risk Evaluation in Geriatric Patients with Type 2 Diabetes Mellitus
Burcu Eren Cengiz, Nurhayat Tugra Ozer, Celil Barlas Cengiz, Yavuz Sultan Selim Akgul, Sibel Akın
Diabetes Metab J. 2026;50(4):808-815.   Published online September 1, 2025
DOI: https://doi.org/10.4093/dmj.2025.0077
  • 5,378 View
  • 149 Download
  • 3 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Type 2 diabetes mellitus (T2DM) is common among older adults and may increase the risk of sarcopenia and frailty. This study evaluated the impact of sarcopenia and frailty on 5-year mortality in older adults with T2DM.
Methods
We assessed a cohort study of 447 adults with T2DM who were more than 60 years old. Following the guidelines set by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), we used bioelectrical impedance analysis to measure muscle mass and a handgrip dynamometer to measure muscle strength. We assessed frailty using the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight (FRAIL) Scale. We categorised the patients into four groups: isolated sarcopenia, isolated frailty, both conditions (sarcopenia and frailty), or neither.
Results
The median age of the patients was 69 years, and 71.6% were female. Isolated sarcopenia was present in 11.0% of patients, isolated frailty in 22.4%, and both sarcopenia and frailty in 9.8%. After adjustment for age, sex, comorbidities, activities of daily living, glycemic control, and nutritional status, sarcopenia and frailty were significantly associated with an increased risk of 5-year mortality. Isolated frailty also significantly predicted mortality (hazard ratio, 2.59; 95% confidence interval, 1.34 to 5.03; P=0.005).
Conclusion
Sarcopenia and frailty were significant predictors of increased mortality risk in older adults with T2DM. Coexisting sarcopenia and frailty posed the highest risk. Early identification and targeted interventions for these conditions in older patients with T2DM are crucial to improving outcomes.

Citations

Citations to this article as recorded by  
  • Sarcopenia and Mortality, Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Juan Du, Xiaoyu Shu, Taiping Lin, Hualong Liao, Liying Zhang, Jirong Yue
    Endocrine Practice.2026;[Epub]     CrossRef
  • The impact of sarcopenia on clinical outcomes in patients with diabetes: A systematic review and meta-analysis of cohort studies
    Ying Tang, Wenyuan Li, Linling Wu, Yunhang Wang, Nini Shi, Jianxun Cao, Jie Zheng, Sujie Shi, Yuxia Ma
    Primary Care Diabetes.2026; 20(3): 264.     CrossRef
  • Overlap between body mass index- and height-adjusted sarcopenic obesity and their association with functional capacity in older adults with diabetes: A study based on the JWGSO consensus
    Satoshi Ida, Kanako Imataka, Tatsuya Tanaka, Kazuya Murata
    Endocrine.2026;[Epub]     CrossRef
  • Reciprocal risks of diabetes and sarcopenia in aging Chinese adults: A prospective cohort study using a semi-Markov multi-state framework
    Yirui Chen, Yinuo Qu, Siyi Kong, Tianyun Wang, Zhiyuan Liu, Huixia Ren, Kai Ma, Tieniu Zhao, Hongwu Wang, Mengyang Wang
    Medicine.2026; 105(26): e49398.     CrossRef
  • Sarcopenia and Frailty in Type 2 Diabetes Mellitus: An Overlooked Challenge
    Chul-Hee Kim
    Diabetes & Metabolism Journal.2026; 50(4): 666.     CrossRef
  • Mitochondrial Proteostasis Links Diabetes and Sarcopenia: Cross-Scale Convergence from Experimental Models to Human Multi-Omics
    Shibo Wei, Soyeon Shin, Dongryeol Ryu, Chang-Myung Oh
    Diabetes & Metabolism Journal.2026; 50(5): 825.     CrossRef
Complications
Article image
Comparison of Efficacy and Safety of Cilostazol/Extract of Ginkgo biloba vs. Aspirin in Carotid Atherosclerosis in Patients with Diabetes Mellitus
You-Cheol Hwang, Mi Kyung Kim, Jung Hwan Park, Han Mi Yun, Sang Yong Kim, Soo Lim
Diabetes Metab J. 2026;50(2):357-367.   Published online August 13, 2025
DOI: https://doi.org/10.4093/dmj.2025.0146
  • 7,312 View
  • 174 Download
  • 4 Web of Science
  • 5 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We conducted a prospective, randomized study to evaluate the combination of cilostazol (CTZ) and extract of Ginkgo biloba (EGb) and compare it with aspirin for the prevention of atherosclerosis progression in patients with type 2 diabetes mellitus (T2DM).
Methods
One hundred five patients with T2DM and increased carotid intima-media thickness (IMT) were randomly assigned to receive either CTZ 200 mg plus EGb 160 mg once daily or aspirin (ASA) 100 mg/day for 12 months. The primary endpoint was the change in maximum carotid IMT.
Results
The mean age and body mass index were 61.6±8.4 years and 25.2±3.1 kg/m2 in the CTZ/EGb group and 61.6±7.6 years and 24.5±3.3 kg/m2 in the ASA group, respectively. CTZ/EGb treatment reduced the maximum IMT in the bulb area (from 1.435±0.690 to 1.346±0.688 mm on the right; from 1.359±0.528 to 1.299±0.528 mm on the left), whereas ASA treatment did not, resulting in significant between-group differences (P<0.05). No significant differences were observed in the common carotid and internal carotid arteries. The CTZ/EGb group showed a reduction in triglycerides and an increase in high-density lipoprotein cholesterol levels. Additionally, aspartate and alanine aminotransferase levels decreased only in the CTZ/EGb group. There were no significant differences in Mini-Mental State Examination (MMSE) score changes or adverse events (ClinicalTrials.gov number: NCT05906199).
Conclusion
Twelve months of CTZ/EGb combination therapy significantly attenuated the progression of carotid atherosclerosis compared with aspirin in patients with T2DM.

Citations

Citations to this article as recorded by  
  • Cilostazol/Extract of Ginkgo biloba or Aspirin, What Is the Treatment in Atherosclerosis Prevention? (Diabetes Metab J 2026;50:357-67)
    Christian Saleh, Ivanka Maduna, Hrvoje Budincevic
    Diabetes & Metabolism Journal.2026; 50(2): 414.     CrossRef
  • Comparison of Efficacy and Safety of Cilostazol/Extract of Ginkgo biloba vs. Aspirin in Carotid Atherosclerosis in Patients with Diabetes Mellitus (Diabetes Metab J 2026;50:357-67)
    You-Cheol Hwang, Sang Yong Kim, Soo Lim
    Diabetes & Metabolism Journal.2026; 50(2): 428.     CrossRef
  • Expert Opinion on Pharmacological Treatment of Diabetic Peripheral Arterial Disease: Clinical Utility of Cilostazol/Ginkgo biloba Extract Combination (Renexin®)
    Hwi Seung Kim, Won Jun Kim, Chang Hoon Lee, Hyunmin Ko, Jun Hwa Hong, Seon Mee Kang, Ah Reum Khang, Soo Kyoung Kim, Sang Joon Park, Yeoree Yang, Tae Jung Oh, Jeehee Yoon, Ju Hee Lee, Jin Woo Jeong, Hochan Cho, Dughyun Choi, Hwa Young Kim, Jung-Hwa Lee, Su
    The Journal of Korean Diabetes.2026; 27(2): 56.     CrossRef
  • Ginkgo biloba L. in preventing cardiovascular disease: pharmacological effects, mechanism of action, and therapeutic potential
    Min Tao, Wei-le Ye, Jiao-jiao Wang, Zhi-ping Liu
    Acta Pharmacologica Sinica.2026;[Epub]     CrossRef
  • Counteracting vascular ageing with Traditional Chinese Medicine: Mechanisms at the cellular and molecular levels
    Xinyu Zhang, Tong Yin, Yanfei Cheng, Yingxin Chang, Zehui Guo, Jia Liu, Jia Shi, Kexuan Tan, Jingjing Yang, Liping Guo, Guanwei Fan, Chuanrui Ma
    Ageing Research Reviews.2026; 122: 103318.     CrossRef
Genetics
Article image
SLC30A8 Rare Variant Modify Contribution of Common Genetic and Lifestyle Factors toward Type 2 Diabetes Mellitus
Hye-Mi Jang, Mi Yeong Hwang, Yi Seul Park, Bong-Jo Kim, Young Jin Kim
Diabetes Metab J. 2026;50(2):385-395.   Published online August 13, 2025
DOI: https://doi.org/10.4093/dmj.2024.0830
  • 5,995 View
  • 129 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study aimed to investigate the modifying effects of rare genetic variants on the risk of type 2 diabetes mellitus (T2DM) in the context of common genetic and lifestyle factors.
Methods
We conducted a comprehensive analysis of genetic and lifestyle factors associated with T2DM in a cohort of 146,284 Korean individuals. Among them, 4,603 individuals developed T2DM during the follow-up period of up to 17 years. We calculated a polygenic risk score (PRS) for T2DM and identified carriers of the rare allele I349F at SLC30A8. A Healthy Lifestyle Score (HLS) was also derived from physical activity, obesity, smoking, diet, and sodium intake levels. Using Cox proportional hazards models, we analyzed how PRS, HLS, and I349F influenced T2DM incidence.
Results
Results showed that high PRS and poor lifestyle were associated with increased risk. Remarkably, I349F carriers exhibited a lower T2DM prevalence (5.7% compared to 11.7% in non-carriers) and reduced the impact of high PRS from 23.18% to 12.70%. This trend was consistent across different HLS categories, with I349F carriers displaying a lower risk of T2DM.
Conclusion
The integration of common and rare genetic variants with lifestyle factors enhanced T2DM predictability in the Korean population. Our findings highlight the critical role of rare genetic variants in risk assessments and suggest that standard PRS and HLS metrics alone may be inadequate for predicting T2DM risk among carriers of such variants.

Citations

Citations to this article as recorded by  
  • Personalised Nutrition in Obesity and Prediabetes: Do Genotypes Matter?
    Magdalena Bossowska, Filip Bossowski, Edyta Adamska-Patruno, Katarzyna Maliszewska, Adam Krętowski
    Nutrients.2026; 18(5): 815.     CrossRef
  • The central role of the β-cell in diabetes: from monogenic forms to type 1, type 2, and gestational diabetes
    Zhaoying Chen, Haipeng Pang
    Reviews in Endocrine and Metabolic Disorders.2026;[Epub]     CrossRef
  • Data-driven diabetes clustering in East Asians: pathological heterogeneity and personalized medicine
    Michio Shimabukuro, Kiriko Watanabe-Shimoji, Hayato Tanabe, Eiryo Kawakami
    The Journal of Clinical Endocrinology & Metabolism.2026;[Epub]     CrossRef
  • Differential contributions of cardiovascular health-related lifestyle factors to epigenetic ageing: implications for healthy longevity
    Da-eun Lee, Yi Seul Park, Hye-Mi Jang, Bong-Jo Kim, Young Jin Kim, Sung-il Cho, Kyeezu Kim
    BMC Medicine.2025;[Epub]     CrossRef
Cardiovascular Risk/Epidemiology
Article image
Associations of Cardiocerebrovascular Risks and Exercise according to Menopausal Status in Women with Type 2 Diabetes Mellitus: A Nationwide Cohort Study
Ji-Hee Ko, Sun Joon Moon, Kyung-Do Han, Hye-Mi Kwon, Se-Eun Park, Eun-Jung Rhee, Won-Young Lee
Diabetes Metab J. 2026;50(1):101-114.   Published online August 13, 2025
DOI: https://doi.org/10.4093/dmj.2024.0487
  • 5,824 View
  • 131 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Menopausal status can increase the risk of cardiocerebrovascular diseases (CCVDs) in women with type 2 diabetes mellitus (T2DM). Regular exercise is well-known to reduce this risk. This study explored the impact of exercise on CCVD and mortality in women with T2DM according to their menopausal status.
Methods
A total of 32,477 premenopausal and 53,690 postmenopausal Korean women with T2DM aged 40 to 60 years from a national health examination cohort (2009 to 2018) were included. We evaluated risks for stroke, myocardial infarction (MI), and mortality based on exercise intensity. Cox proportional hazard regression analyses were performed to obtain the adjusted hazard ratio (aHR) and 95% confidence interval.
Results
Exercise reduced stroke, MI, and mortality risks in women with T2DM, regardless of menopausal status. The highest effects of aHR compared to the sedentary group were 0.68 for stroke, 0.66 for MI, and 0.81 for mortality. Postmenopausal women experienced significant MI risk reductions at most exercise intensities, with the greatest reduction in the ≥1,500 metabolic equivalent of task score group unlike premenopausal women. However, stroke and mortality risk reductions in postmenopausal women were less pronounced compared to premenopausal women.
Conclusion
Exercise reduces CCVD risk in women with T2DM across menopausal status. Postmenopausal women with T2DM had more benefits from exercise on MI but fewer benefits on stroke and mortality than premenopausal women. In premenopausal women with T2DM, exercise was not associated with a lower MI risk.
Pharmacotherapy
Article image
New Users of Sodium-Glucose Cotransporter 2 Inhibitors Are at Low Risk of Prostate Cancer: A Nationwide Cohort Study
Yun Kyung Cho, Sehee Kim, Myung Jin Kim, Woo Je Lee, Ye-Jee Kim, Chang Hee Jung
Diabetes Metab J. 2026;50(1):90-100.   Published online July 22, 2025
DOI: https://doi.org/10.4093/dmj.2024.0693
  • 6,839 View
  • 134 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Preclinical studies have reported anticancer properties of sodium-glucose cotransporter 2 inhibitors (SGLT2is). We aimed to elucidate the association between the use of SGLT2is and the risk of prostate cancer among male patients with type 2 diabetes mellitus (T2DM).
Methods
An active-comparator, new-user cohort design using a nationwide database between September 2014 and June 2020 was conducted on 45,601 new SGLT2i users and 205,395 new users of other glucose-lowering medications (oGLMs). In the following 1:1 propensity score matched (PSM) analysis, 35,371 SGLT2i users matched with an equivalent number of oGLM users were assessed. The hazard ratios (HRs) and 95% confidence intervals (CIs) for prostate cancer were calculated.
Results
Among the cohort, prostate cancer was diagnosed in 210 out of 45,601 SGLT2i users, corresponding to a cumulative incidence of 1.0%, in contrast to 1,880 cases among 205,395 users of oGLMs, with a cumulative incidence of 1.5%. The use of SGLT2is was significantly correlated with a reduced risk of prostate cancer based on a multivariable-adjusted HR of 0.83 (95% CI, 0.71 to 0.98). PSM analysis affirmed 18% reduction in prostate cancer risk associated with SGLT2i use (HR, 0.82; 95% CI, 0.67 to 0.99). Subgroup analyses revealed that body mass index (BMI) significantly influenced the effect of SGLT2i on prostate cancer risk, with a more pronounced reduction in the subgroup with a BMI <25 kg/m2 (P=0.037).
Conclusion
The use of SGLT2is in Korean male patients with T2DM is associated with a lower risk of prostate cancer.

Citations

Citations to this article as recorded by  
  • Sodium-Glucose Cotransporter 2 Inhibitors as Emerging Anticancer Agents
    Yun Kyung Cho, Chang Hee Jung
    Diabetes & Metabolism Journal.2026; 50(1): 1.     CrossRef
  • Anti-diabetic Drugs and Cancer: Integrated Mechanisms of Tumor Suppression and Clinical Translation
    Mahya Asadalizadeh, Mohammad Kazem Molavi Rahbar, Tabassom Mahmoudie, Mahshid Abbasi, Mitra Akbari, Davoud Shakiba, Aida Mohammadiun Shabestari, Meysam Ebrahimifar
    Indian Journal of Clinical Biochemistry.2026;[Epub]     CrossRef
Review
Others
Article image
Differences between Type 2 Diabetes Mellitus and Obesity Management: Medical, Social, and Public Health Perspectives
Soo Lim, Ga Eun Nam, Arya M. Sharma
Diabetes Metab J. 2025;49(4):565-579.   Published online June 11, 2025
DOI: https://doi.org/10.4093/dmj.2025.0278
  • 12,464 View
  • 349 Download
  • 7 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   ePub   
Obesity and type 2 diabetes mellitus (T2DM) are among the most urgent global public health challenges, yet differ markedly in recognition and management across medical, social, infrastructure, and policy domains. T2DM is supported by clear diagnostic criteria, defined treatment targets, and broad acceptance as a chronic disease. In contrast, obesity is assessed using imprecise metrics like body mass index, lacks standardized treatment goals, and is often misunderstood as a lifestyle issue rather than a chronic, relapsing disease. This misconception contributes to stigma, discrimination, and unrealistic patient expectations. T2DM receives substantial research funding, comprehensive clinical guidelines, and structured medical education, with strong support from large professional societies and multidisciplinary care models. Obesity care remains underfunded, inconsistently delivered, and underrepresented in medical training. Public health and policy efforts strongly favor T2DM, providing coordinated programs, insurance coverage, and regulatory oversight. Conversely, obesity is marginalized, with limited policy influence and a largely unregulated commercial weight-loss industry. Bridging these disparities requires adopting lessons from T2DM management—such as evidence-based guidelines, improved provider training, expanded insurance coverage, and public health strategies—to enhance obesity care and recognize it as a chronic disease requiring long-term, structured management.

Citations

Citations to this article as recorded by  
  • Diabetes Fact Sheet 2025: Special Edition on Diabetes with Obesity and in Pregnancy
    Se Eun Park, Se Hee Min, Jin Hwa Kim, Seung-Hwan Lee, Han Na Jung, Joon Ho Moon, Kyungdo Han, Seung-Hyun Ko, Bong Soo Cha, Sung Hee Choi
    Diabetes & Metabolism Journal.2026; 50(2): 255.     CrossRef
  • Diabetes Fact Sheet 2025: Comparative Epidemiology and Clinical Features of Obese and Non-Obese Diabetes in Korea
    Jin Hwa Kim, Bongseong Kim, Se Eun Park, Seung-Hyun Ko, Sung Hee Choi, Bong Soo Cha, Kyungdo Han, Seung-Hwan Lee
    Diabetes & Metabolism Journal.2026; 50(2): 267.     CrossRef
  • Association Between Anthropometric Indices and Presence of Type 2 Diabetes Mellitus in Obesity
    Shehla Shaikh, Sambit Das, Sunil Kota, Nitin Kapoor, Sanjay Kalra, Saptarshi Bhattacharya
    Diabetes Therapy.2026; 17(7): 997.     CrossRef
  • Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions
    Wen-Ting He, Yi-Di Song, Xin-Yu Wang, Si-Yuan He, Xue Tao, Shi-Xuan Yuan, Liang Zhou, En-Wu Long
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • ARF6: Biomarker, Therapeutic Target, and AI-Driven Precision Management for Type 2 Diabetes with Obesity
    Yangyang Wang, Ye Chen, Huiyan Wang
    Metabolites.2026; 16(10): 769.     CrossRef
  • GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
    Megha Pawar, Chandrashekhar Patil, Zubershaha Fakir, Durgesh Pagar, Sunil Mahajan
    BioMed Target Journal.2025; 3(2): 18.     CrossRef
Original Articles
Metabolic Risk/Epidemiology
Article image
Ultra-Processed Food Intake and Risk of Type 2 Diabetes Mellitus: A Dose-Response Meta-Analysis of Prospective Studies
Yujin Kim, Yoonkyoung Cho, Jin Eui Kim, Dong Hoon Lee, Hannah Oh
Diabetes Metab J. 2025;49(5):1064-1074.   Published online June 9, 2025
DOI: https://doi.org/10.4093/dmj.2024.0706
Correction in: Diabetes Metab J 2026;50(1):211
  • 18,172 View
  • 564 Download
  • 18 Web of Science
  • 14 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Although some studies suggest a positive association between ultra-processed food (UPF) intake and type 2 diabetes mellitus (T2DM), little is known about the exact shape and risks associated with different units (percentage of g/day, absolute g/day, serving/day) of UPF intake and whether the association is independent of diet quality, total energy intake, and body mass index (BMI).
Methods
Prospective studies published through January 2024 were identified by searching PubMed, Embase, and Web of Science. Summary relative risks (RRs) and 95% confidence intervals (CIs) were estimated using random-effects models. A nonlinear dose-response meta-analysis was conducted using restricted cubic spline analysis.
Results
After screening 569 publications, a total of 12 prospective cohort studies were included. Comparing the highest vs. lowest categories of intake, summary RR for T2DM risk was 1.48 (95% CI, 1.36 to 1.61). Higher summary RRs were observed among studies from Europe and North America. Among individual UPF subgroups, processed meats (summary RR, 1.34; 95% CI, 1.16 to 1.54) were positively associated, whereas ultra-processed cereals and breads (0.98; 95% CI, 0.97 to 0.99) and packaged savory snacks (0.92; 95% CI, 0.88 to 0.95) were inversely associated. The summary RRs associated with every 10% (of g/day), 100-g/day, and 1-serving/day increase in UPF intake were 1.14 (95% CI, 1.11 to 1.17), 1.05 (95% CI, 1.03 to 1.06), and 1.04 (95% CI, 1.03 to 1.05), respectively. The dose-response curve for absolute g/d intake suggested nonlinearity, showing a steeper risk increase approximately at >300 g/day. The associations persisted after adjustment for diet quality, energy intake, or BMI.
Conclusion
Our data suggest that UPF intake increases diabetes risk, with a potential threshold effect at 300 g/day.

Citations

Citations to this article as recorded by  
  • Ultra-Processed Food Intake and Risk of Type 2 Diabetes Mellitus: A Dose-Response Meta-Analysis of Prospective Studies (Diabetes Metab J 2025;49:1064-74)
    Lirong Hu, Aiji Chen, Gang Tian
    Diabetes & Metabolism Journal.2026; 50(1): 194.     CrossRef
  • Ultra-Processed Food Intake and Risk of Type 2 Diabetes Mellitus: A Dose-Response Meta-Analysis of Prospective Studies (Diabetes Metab J 2025;49:1064-74)
    Yujin Kim, Hannah Oh
    Diabetes & Metabolism Journal.2026; 50(1): 208.     CrossRef
  • Dietary Patterns, Cooking Methods, and Their Association with Prediabetes Risk Markers in Romanian University Students: A Cross-Sectional Analysis
    Teodora Piroș, Raluca Lupusoru, Lavinia Cristina Moleriu, Călin Muntean, Radu Dumitru Moleriu, Dora Mihalea Cîmpian, Mădălina Gabriela Cincu, Elena Gabriela Strete, Amalia Gabriela Timofte, Ruxandra-Cristina Marin
    Nutrients.2026; 18(6): 977.     CrossRef
  • Commentary on the Dietary Guidelines for Americans 2026–2030
    Douglas Taren, Robert Bandsma, Alejandra Cantoral, Chi Chen, Brian Finck, Corrine Hanson, Gang Hu, Nicole Kellow, Kathleen Holton, Hanqi Luo, Joshua Miller, Maurizio Muscaritoli, Muzi Na, Rachel Novotny, Omar Ramos-Lopez, Manuel Ruz, Krista Varady, Saroja
    Nutrition Reviews.2026;[Epub]     CrossRef
  • Associations between dietary food categories, epigenetic age acceleration and low-grade inflammation in the Lifelines-DEEP cohort
    Laura Bordoni, Fatemeh Mansouri, Chiara Rucci, João Agostinho de Sousa, Ferdinand von Meyenn
    Clinical Nutrition.2026; 63: 106703.     CrossRef
  • Ultra-processed food consumption and the trajectory of cardio-renal-metabolic multimorbidity: insights from multi-state modelling
    Shuzhen Zhao, Chengnan Guo, Xin Zhang, Yi Li, Jingkun Hu, Jiayi Huang, Luojia Dai, Zhenqiu Liu, Tiejun Zhang
    Food & Function.2026; 17(14): 6478.     CrossRef
  • The association between ultra-processed food consumption and incidence of cardio-renal-metabolic multimorbidity: Tehran Lipid and Glucose Study
    Emad Alem, Somayeh Hosseinpour-Niazi, Parvin Mirmiran, Fereidoun Azizi
    Nutrition, Metabolism and Cardiovascular Diseases.2026; 36(11): 104855.     CrossRef
  • Nutrition and cardiometabolic health in cystic fibrosis: Emerging evidence and research gaps
    Veronica Lynch, Joanne Barrett, Sarah Collins, Paige Elliott, Darren Sills, Joanna Snowball, Pauline Douglas, Alan R Smyth, Audrey Tierney, Damian G. Downey, Claire McEvoy
    Journal of Cystic Fibrosis.2026;[Epub]     CrossRef
  • When ultra-processed food is clinically indicated: Oral nutritional supplements and the limits of the nova paradigm in clinical nutrition
    Jimmy Chun Yu Louie
    Clinical Nutrition.2026; 65: 106769.     CrossRef
  • Total ultra-processed food intake and selected food-group exposures in relation to non-alcoholic fatty liver disease: a systematic review and meta-analysis
    Dongmei Chen, Ling Li, Chenglong Zhang
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Geographic Patterns of Pancreatic Cancer Mortality and Dietary Microplastic Exposure in Italy: An Ecological Hypothesis-Generating Framework
    Masoumeh Khamehchi, Umberto Cornelli, Rafael Luque, Claudio Casella
    Microplastics.2026; 5(3): 184.     CrossRef
  • Ultra-Processed Food Consumption and Risk of Type 2 Diabetes in the Melbourne Collaborative Cohort Study
    Priscila Machado, Natalia Tolstova, Melissa Lane, Caroline Costa, Euridice Martinez Steele, Fernanda Rauber, Renata B. Levy, Sarah A. McNaughton, Mark Lawrence, Carlos A. Monteiro, Allison Hodge
    Journal of the Academy of Nutrition and Dietetics.2026; 126(12): 156434.     CrossRef
  • Effects of ultra-processed food reduction intervention on postprandial glucose and glycaemic variability in Korean young adults: study protocol for the ULTRA-CGM randomised controlled trial
    Yujin Kim, Dabin Jeong, Jiyoon Lee, Sooran Yang, Megan S Rojas Guzman, Jihoon You, Jeongsoo Lim, Sujin Lee, Hannah Oh
    BMJ Open.2026; 16(10): e120830.     CrossRef
  • Trends in sales of sugar-sweetened beverages and associated type 2 diabetes burden in nine African countries: an ecological time-series analysis
    Caroline H. Karugu, Gershim Asiki, Senzo Mthembu, Samuel Iddi, Peter M. Kaberia, Shukri F. Mohamed, Richard E. Sanya, Sylvia Kiwuwa-Muyingo, Stefanie Vandevijvere, Charles Agyemang
    Global Health Action.2025;[Epub]     CrossRef
Basic and Translational Research
Article image
Anti-Senescence Effect of Inhibiting Sodium-Glucose Cotransporter 2 and α-Glucosidase in a Type 2 Diabetes Mellitus Animal Model
Serin Hong, Byung Soo Kong, Hyunsuk Lee, Young Min Cho
Diabetes Metab J. 2025;49(6):1229-1241.   Published online May 22, 2025
DOI: https://doi.org/10.4093/dmj.2024.0339
  • 7,199 View
  • 186 Download
  • 2 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The prevalence of type 2 diabetes mellitus (T2DM) increases with age, and cellular senescence of pancreatic β-cells plays a key role in T2DM pathogenesis. As canagliflozin and acarbose have been shown to increase lifespan in mice, we investigated the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitor, α-glucosidase inhibitor or both on the cellular senescence of β-cells in a T2DM mouse model.
Methods
Enavogliflozin (0.3 mg/kg), acarbose (10 mg/kg), or vehicle was orally administered daily to db/db mice for 6 weeks. The levels of senescence markers (p16, p21, and p53) in the pancreas and kidney were measured through real-time polymerase chain reaction (PCR), immunofluorescence staining, and Western blot. In an in vitro analysis, isolated pancreatic islets were exposed to H2O2 to induce cellular senescence, then treated with β-hydroxybutyrate (β-HB), and subsequently assessed for levels of senescent markers.
Results
Enavogliflozin alone or combined with acarbose effectively lowered blood glucose levels in db/db mice. The combined treatment resulted in the greatest increase in β-cell function calculated using insulinogenic index and homeostasis model assessment of β-cell function compared to the vehicle. Additionally, the combined treatment significantly reversed the increase in p16, with a similar trend observed in p21 and p53 in the islets. Treatment increased circulating β-HB and in vitro analysis suggested the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) by β-HB in reducing senescence in the islets.
Conclusion
The combined administration of enavogliflozin and acarbose significantly reduced blood glucose, improved β-cell function, and reduced senescent β-cells in db/db mice. This combination therapy holds potential as a senotherapeutic strategy for managing T2DM.

Citations

Citations to this article as recorded by  
  • Microneedle strategies for diabetic wound management: A comprehensive review of materials, mechanisms, and therapeutic outcomes
    Kaustubh Naik, Kanhaiya Singh
    Materials Today Advances.2026; 29: 100684.     CrossRef
Metabolic Risk/Epidemiology
Article image
Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study
Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
Diabetes Metab J. 2025;49(6):1287-1297.   Published online May 21, 2025
DOI: https://doi.org/10.4093/dmj.2024.0601
  • 11,596 View
  • 182 Download
  • 4 Web of Science
  • 5 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
In this study, we aimed to determine the metabolic characteristics and changes in the early stages of young-onset type 2 diabetes mellitus (YOD) in Koreans.
Methods
From the Anam Diabetes Observational Study cohort (2017–2023), the characteristics of newly diagnosed YOD (<40 years of age, n=39) and later-onset (≥40 years of age) type 2 diabetes mellitus (LOD, n=178) were compared at diagnosis and 1 year later. All participants underwent an oral glucose tolerance test at diagnosis and annually thereafter. β-Cell function was determined using the disposition index (DI), calculated as the insulinogenic index×Matsuda insulin sensitivity index (ISI). Insulin sensitivity was determined using ISI and homeostasis model assessment of insulin resistance (HOMA2-IR).
Results
Mean (±standard deviation) age of individuals with YOD was 29.8±6.4 years, and 76.9% were male. YOD patients had higher body mass index (29.8 kg/m2 vs. 27.2 kg/m2, P=0.020), fat mass (30.5 kg vs. 24.1 kg, P=0.011), fatty liver index (65.4 vs. 49.2, P=0.005), and glycosylated hemoglobin (HbA1c) level at diagnosis (9.3% vs. 7.7%, P<0.001) compared with LOD patients. YOD patients exhibited lower insulin sensitivity (ISI: 2.79 vs. 3.26, P=0.008; HOMA2-IR: 2.72 vs. 1.83, P<0.001) and β-cell function (DI) at diagnosis (0.41 vs. 0.72, P=0.003) than LOD patients. Following 1 year of treatment, DI improved by 94% in YOD along with improvement in HbA1c; however, it was still significantly lower than that of LOD (0.64 vs. 0.90, P=0.017).
Conclusion
Individuals with YOD have unfavorable metabolic characteristics, substantially reduced insulin sensitivity, and decompensated β-cell function at disease onset, which persist even after treatment.

Citations

Citations to this article as recorded by  
  • Compensated But Failing: Early β‐Cell Dysfunction Under Normoglycemia in Children and Adolescents With Overweight and Obesity
    Paulina Correa‐Burrows, Estela Blanco, Raquel Burrows
    Diabetes/Metabolism Research and Reviews.2026;[Epub]     CrossRef
  • Remission in Young-Onset Type 2 Diabetes: Mechanisms, Intervention Strategies, and Predictive Factors
    易宏 邹
    Advances in Clinical Medicine.2026; 16(05): 301.     CrossRef
  • Targeting Mitochondria in Aging‐Related Diseases: Therapeutic Potential and Obstacles
    Zijie Xiang, Yu Chen, Xishui Liu, Haowen Lu, Yuqing Yang, Lei Xing, Yu Zhang, Chuandong Lang, Siming Zhang, Shixiang Zhao, Youzhi Hong, Jiaxiang Bai, Yusen Qiao
    MedComm.2026;[Epub]     CrossRef
  • Circulating GDF15 levels reflect metabolic and inflammatory burden in early dysglycemia: findings from the ADIOS cohort
    Ji Yoon Kim, Ah Hyeon Lee, Jiyoon Lee, Hye-Min Jang, Sin Gon Kim, Dong-Hoon Kim, Nam Hoon Kim
    Diabetes Research and Clinical Practice.2026; 239: 113461.     CrossRef
  • Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
    Ji Yoon Kim, Nam Hoon Kim
    Diabetes & Metabolism Journal.2026; 50(5): 844.     CrossRef
Complications
Article image
Impact of Remnant Cholesterol on the Risk for End-Stage Renal Disease in Type 2 Diabetes Mellitus: A Nationwide Population-Based Cohort Study
Eun Roh, Ji Hye Heo, Han Na Jung, Kyung-Do Han, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
Diabetes Metab J. 2025;49(5):1106-1115.   Published online May 21, 2025
DOI: https://doi.org/10.4093/dmj.2024.0406
  • 6,137 View
  • 169 Download
  • 5 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Remnant cholesterol (remnant-C) has been linked to the risk of various vascular diseases, but the association between remnant-C and end-stage renal disease (ESRD) in patients with type 2 diabetes mellitus (T2DM) remains unclear.
Methods
Using a nationwide cohort, a total of 2,537,149 patients with T2DM without ESRD, who had participated in the national health screening in 2009, were enrolled and followed up until 2020. Low-density lipoprotein cholesterol (LDL-C) levels were assessed by the Martin-Hopkins method, and remnant-C was calculated as total cholesterol–LDL-C–high-density lipoprotein cholesterol.
Results
During a median follow-up period of 10.3 years, 26,246 patients with T2DM (1.03%) developed ESRD. Participants in the upper quartile of remnant-C had a higher risk of ESRD, with hazard ratios of 1.12 (95% confidence interval [CI], 1.08 to 1.17), 1.20 (95% CI, 1.15 to 1.24), and 1.33 (95% CI, 1.26 to 1.41) in the second, third, and fourth quartile, compared with the lowest quartile, in multivariable-adjusted analyses. The positive association between remnant-C and ESRD remained consistent, irrespective of age, sex, presence of pre-existing comorbidities, and use of anti-dyslipidemic medications. The increased risk of ESRD was more pronounced in high-risk subgroups, including those with hypertension, chronic kidney disease, obesity, and a longer duration of diabetes.
Conclusion
These findings suggest that remnant-C profiles in T2DM have a predictive role for future progression of ESRD, independent of traditional risk factors for renal dysfunction.

Citations

Citations to this article as recorded by  
  • Impact of Remnant Cholesterol on the Risk for End-Stage Renal Disease in Type 2 Diabetes Mellitus: A Nationwide Population-Based Cohort Study (Diabetes Metab J 2025;49:1106-15)
    Jun Hwa Hong
    Diabetes & Metabolism Journal.2026; 50(1): 190.     CrossRef
  • A Narrative Review of Remnant Cholesterol as an Independent Atherogenic Lipoprotein in Type 2 Diabetes: Pathophysiology and Clinical Implications
    Ramdhani Natsir, Eli Halimah, Ajeng Diantini, Jutti Levita
    Therapeutics and Clinical Risk Management.2026; Volume 22: 1.     CrossRef
  • Uromodulin: A Novel Regulator of the Kidney–Adipose Axis in Diabetic Kidney Disease
    Linan Cheng, Zheyu Xing, Di Song, Nan Hu, Chunyue Wang, Yuqing Chen
    International Journal of Molecular Sciences.2026; 27(13): 6009.     CrossRef
  • Association of remnant cholesterol with kidney outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
    Jie Gao, Jiaqi Wang, Zhangli Wang
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
Metabolic Risk/Epidemiology
Article image
Predictive Models for Type 2 Diabetes Mellitus in Han Chinese with Insights into Cross-Population Applicability and Demographic Specific Risk Factors
Ying-Erh Chen, Djeane Debora Onthoni, Shao-Yuan Chuang, Guo-Hung Li, Yong-Sheng Zhuang, Hung-Yi Chiou, Wayne Huey-Herng Sheu, Ren-Hua Chung
Diabetes Metab J. 2025;49(6):1272-1286.   Published online May 21, 2025
DOI: https://doi.org/10.4093/dmj.2024.0319
  • 7,859 View
  • 142 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The rising global incidence of type 2 diabetes mellitus (T2DM) underscores the need for predictive models that enhance early detection and prevention across diverse populations. This study aimed to identify predictors of incident T2DM within a Han Chinese population, assess their impact across various age and sex demographics, and explore their applicability to European populations.
Methods
Using data from about 65,000 participants in the Taiwan Biobank (TWB), we developed a predictive model, achieving an area under the receiver operating characteristic curve of 90.58%. Key predictors were identified through LASSO regression within the TWB cohort and validated using over 4 million records from Taiwan’s Adult Preventive Healthcare Services (APHS) program and the UK Biobank (UKB).
Results
Our analysis highlighted 13 significant predictors, including established factors like glycosylated hemoglobin (HbA1c) and blood glucose levels, and less conventionally considered variables such as peak expiratory flow. Notable differences in the effects of HbA1c levels and polygenic risk scores between the TWB and UKB cohorts were observed. Additionally, age and sex-specific impacts of these predictors, detailed through APHS data, revealed significant variances; for instance, waist circumference and diagnosed mixed hyperlipidemia showed greater impacts in younger females than in males, while effects remained uniform across male age groups.
Conclusion
Our findings offer novel insights into the diagnosis and management of diabetes for the Han Chinese and potentially for broader East Asian populations, highlighting the importance of ethnic and demographic diversity in developing predictive models for early detection and personalized intervention strategies.

Citations

Citations to this article as recorded by  
  • Plasminogen activator inhibitor-1, vaspin, and dietary inflammatory index in relation to cardiometabolic health in diabetic women
    Sule Kocabas, Nevin Sanlier
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • The Relationship Between High-Density Lipoprotein (HDL) and Glycated Hemoglobin (HbA1C) in Type 2 Diabetes Mellitus Patients: Implications for Cardiovascular Risk
    Setyoadi Setyoadi, Dina Dewi Sartika Lestari Ismail, Annisa Wuri Kartika, Dewi Purnama Sari, Angel Dwi Septian, Adelina Stefanie Lallo, Rara Kurniasari
    Journal of Rural Community Nursing Practice.2025; 3(2): 234.     CrossRef
Review
Basic and Translational Research
Article image
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
Joon Seok Park, Kyu Sik Kim, Hyung Jin Choi
Diabetes Metab J. 2025;49(3):333-347.   Published online May 1, 2025
DOI: https://doi.org/10.4093/dmj.2025.0106
  • 19,143 View
  • 552 Download
  • 43 Web of Science
  • 49 Crossref
AbstractAbstract PDFPubReader   ePub   
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as blockbuster drugs for treating metabolic diseases. Glucagon-like peptide-1 (GLP-1) plays a pivotal role in glucose homeostasis by enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and acting on the central nervous system to regulate satiation and satiety. This review summarizes the discovery of GLP-1 and the development of GLP-1RAs, with a particular focus on their central mechanisms of action. Human neuroimaging studies demonstrate that GLP-1RAs influence brain activity during food cognition, supporting a role in pre-ingestive satiation. Animal studies on hypothalamic feed-forward regulation of hunger suggest that cognitive hypothalamic mechanisms may also contribute to satiation control. We highlight the brain mechanisms of GLP-1RA-induced satiation and satiety, including cognitive impacts, with an emphasis on animal studies of hypothalamic glucagon-like peptide-1 receptor (GLP-1R) and GLP-1R-expressing neurons. Actions in non-hypothalamic regions are also discussed. Additionally, we review emerging combination drugs and oral GLP-1RA formulations aimed at improving efficacy and patient adherence. In conclusion, the dorsomedial hypothalamus (DMH)—a key GLP-1RA target—mediates pre-ingestive cognitive satiation, while other hypothalamic GLP-1R neurons regulate diverse aspects of feeding behavior, offering potential therapeutic targets for obesity treatment.

Citations

Citations to this article as recorded by  
  • Semaglutide beyond weight loss: Mechanistic insights and functional paradoxes from the SEMALEAN study
    Shambo S. Samajdar, Shashank Joshi
    Diabetes, Obesity and Metabolism.2026; 28(1): 779.     CrossRef
  • Tirzepatide and Obesity: A Narrative Review
    Arya Singh, Rahnuma Ahmad, Kona Chowdhury, Mahendra Narwaria, Mainul Haque
    Advances in Human Biology.2026; 16(2): 290.     CrossRef
  • An expert narrative review on the brain-kidney axis in diabetic kidney disease: Mechanisms and therapeutic insights
    Zongrui Zhang, Rangzi Yi, Shihong Xiong, Yushu Zhang, Xuebin Cao, Wenqi Zhen, Yang Yang, Na Gong
    Diabetes Research and Clinical Practice.2026; 233: 113055.     CrossRef
  • Impaired Brain Incretin and Gut Hormone Expression in Human Alcohol-Related Brain Damage: Opportunities for Therapeutic Targeting
    Suzanne M. de la Monte, Ming Tong, Rolf I. Carlson, Greg Sutherland
    Biomolecules.2026; 16(1): 99.     CrossRef
  • Plasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities
    Houda Zoubiri, Wassila Saiah, Amel Otmane, Hamza Saidi, Mohamed Makrelouf, Samir Ait Abderrhmane, Ali El Mahdi Haddam, Elhadj-Ahmed Koceir
    International Journal of Molecular Sciences.2026; 27(3): 1218.     CrossRef
  • The Enterolimbic Axis: Gut-Brain Affective Circuits at the Crossroad of Metabolism, Emotion, and Behavior
    Antonio Gasbarrini, Francesca Sofia Galli, Gianluca Ianiro, Francesca Ponziani, Emanuele Rinninella
    American Journal of Gastroenterology.2026; 121(8): 1819.     CrossRef
  • Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity
    Andrijana Koceva, Andrej Janež, Tajda Pečko, Mojca Jensterle
    Nutrients.2026; 18(4): 677.     CrossRef
  • National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
    HK Chopra, Ashwani Mehta, CK Ponde, Navin C Nanda, GS Wander, Abraham Oomman, Prafulla Kerkar, SN Routray, GP Ratnaparkhi, Prashant Advani, Rituparna Shinde, Rajeev Agarwal, Ajay Mahajan, Jay Shah, Gaurav Verma, Sanjay Mittal, Dorairaj Prabhakar, D Ramesh
    Journal of The Association of Physicians of India.2026; 74(2): e8.     CrossRef
  • Polysaccharides from Acanthopanax senticosus (Rupr. et Maxim.) Harms: Molecular Messengers Linking the Traditional Efficacy of Fortifying the Spleen, Replenishing Qi, and Calming the Spirit to Gut-Immune Axis Regulation
    Bichun Hu, Deyong Zeng, Junli Liu, Weiping Wang, Shuaimin Hu, Weihong Lu
    Journal of Future Foods.2026;[Epub]     CrossRef
  • Obestatin: canonical and unexpected functions
    Icia Santos-Zas, Uxia Gurriaran-Rodriguez, Tania Cid-Diaz, Saul Leal-Lopez, Felipe F. Casanueva, Yolanda Pazos-Randulfe, Jesus P. Camiña
    Reviews in Endocrine and Metabolic Disorders.2026; 27(2): 317.     CrossRef
  • The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis
    Junjie Lin, Rongtao Yang, Jiacheng Zhuang, Wenbo Zhang, Qiang Tong, Jiahui Liu, Ye Kang, Yuan Yuan
    Journal of Ovarian Research.2026;[Epub]     CrossRef
  • Hypothalamus-liver talks: whispers in the language of metabolism
    Vitor Ferreira, Iara Fernández-González, Jane Jose Vattathara, Amanda Rodríguez-Díaz, Paola Fernández-Sanmartín, Carlos Diéguez
    Reviews in Endocrine and Metabolic Disorders.2026; 27(3): 519.     CrossRef
  • Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance
    Ruxandra Cristina Marin, Cosmin Mihai Vesa, Delia Mirela Tit, Andrei-Flavius Radu, Gabriela S. Bungau
    International Journal of Molecular Sciences.2026; 27(7): 2988.     CrossRef
  • Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders
    Yun Kyung Cho, Chang Hee Jung
    Clinical and Molecular Hepatology.2026; 32(2): 464.     CrossRef
  • Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis
    Mehmet Kanbay, Sama Mahmoud Abdel-Rahman, Mustafa Guldan, Lasin Ozbek, Nur I Genc, Ahmet B Ak, Adrian Covic, Hayri K Goren
    Clinical Kidney Journal.2026;[Epub]     CrossRef
  • DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model
    Linda Sasset, Andrew D. Cameron, Carleigh Sussman, Luisa Rubinelli, Debnath Maji, Robert Miller, Andy Thompson, Delcora Campbell, Melanie R. Walker, Marek M. Drozdz, Rachel A. Liberatore
    Molecular Therapy Nucleic Acids.2026; 37(2): 102946.     CrossRef
  • Causes and consequences of discontinuation of GLP1RAs or tirzepatide
    Antonio Ceriello, Francesco Prattichizzo, Abdul Raouf Mastan Sheik Abdullah, Rosalba La Grotta, Cesare Celeste Berra, Barbara McGowan, Alicia Jenkins, Neale Cohen, Michael Albrecht Nauck, Giuseppina Tiziana Russo
    Nature Reviews Endocrinology.2026; 22(9): 530.     CrossRef
  • Sweet killers: Animal toxins that mimic glucoregulatory hormones
    Isabela Gobbo Ferreira, Beatriz de Cássia da Silva Jacob, Emilly Regina Ramos, Lorena de Oliveira Agati, Beatriz de Castro Vieira, Manuela Berto Pucca, Eloise Trostdorf Filardi, Eliane Candiani Arantes, Isadora Sousa de Oliveira
    Toxicon.2026; 281: 109181.     CrossRef
  • Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension
    Benoit Aguado, Thomas Lacoste-Palasset, Grégoire Ruffenach, Fabrice Bauer, Laurent Savale, Marc Humbert, David Montani, Fabrice Antigny
    ERJ Open Research.2026; 12(3): 01479-2025.     CrossRef
  • Altered hypothalamic functional connectivity in adolescents with severe obesity
    Allison L. B. Shapiro, Meghan E. Pauley, Jaime M. Moore, Lucy Hall, Nicholas Stence, Susan L. Johnson, Kristen J. Nadeau, Kathleen L. Keller, Barbara J. Rolls, Marc-Andre Cornier, Jason R. Tregellas
    International Journal of Obesity.2026; 50(8): 1818.     CrossRef
  • Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance
    Raynier Zambrano-Villacres, Martín Campuzano-Donoso, Claudia Reytor-González, Gianluca Rossetti, Luigi Cobellis, Francesco Cobellis, Vincenzo Pilone, Daniel Simancas-Racines, Luigi Schiavo
    Nutrients.2026; 18(11): 1751.     CrossRef
  • Circadian rhythms of gut microbiota modulate nocturnal hyperglycemia in type 2 diabetes: a comprehensive review on mechanisms and chrono-targeted interventions
    Hanchi Ying, Qi Wang, Qian He, Yibo Cao, Guangyao Wei, Zhiqiang Xiao, Xiaoting Luo
    Frontiers in Microbiology.2026;[Epub]     CrossRef
  • Targeting the GLP-1 receptor pathways for dual management of obesity and depression
    Ruchi Keswani, Shvetank Bhatt
    Drug Discovery Today.2026; 31(4): 104727.     CrossRef
  • Hypothalamic orexigenic and anorexigenic neuropeptides in the rotenone model of Parkinson’s disease
    Zsombor Márton, Bence Pytel, Dávid Kovács, Máté Szabó, Zsófia Havasi, Gergely Berta, József Farkas, László Ákos Kovács, Nóra Füredi, Viktória Kormos, Balázs Gaszner
    Scientific Reports.2026;[Epub]     CrossRef
  • Direct effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: A systematic review and meta-analysis
    Zoe Lee Greenblatt, Atena Tork, Ivy Cruz, Erik D. Fausak, Huy-an Tran, Mahima Krovidy, Cecilia Giulivi
    Metabolism Open.2026; 31: 100484.     CrossRef
  • Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review
    Jenyfer M Fuentes-Mendoza, Marcio J Concepción-Zavaleta, Luisa Graciela Dongo-Dueñas, Jose Mariano J Jara-Pianto, Jhosmar Angel Sierra-Martel, Claudio Aldahir Medina-Angulo, Horus Michael Virú-Flores, Jeny J Mendoza-Godoy, Francisca E Zavaleta-Gutiérrez,
    World Journal of Clinical Pediatrics.2026;[Epub]     CrossRef
  • Design, synthesis, and biological activity of novel oxazole-based small molecule allosteric GLP-1R agonists
    Ruifeng Wang, Qing Liu, Chaoyu Lu, Ke Chen, Shuihua Liu, Liyuan Guo, Zhengmin Guo, Yunfeng Liu, Yi Zhang
    European Journal of Medicinal Chemistry.2026; 318: 119206.     CrossRef
  • Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice
    Mika Sawada, Naoko Nakanishi, Masakazu Aihara, Kanako Ohkuma, Shoko Hamano, Yoshitaka Sakurai, Rie Sekine, Satoshi Usami, Toshimasa Yamauchi, Naoto Kubota
    Endocrinology, Diabetes & Metabolism.2026;[Epub]     CrossRef
  • Hidden Malnutrition in the GLP-1 Era: Micronutrient Status, Protein Adequacy, and Lean Mass as Emerging Nutritional Considerations—A Narrative Review
    Tamara Sorić, Ana Sarić, Andrija Ivanišin, Mario Lovrić, Mirta Milić, Martina Matovinović, Marijana Matek Sarić
    Nutrients.2026; 18(17): 2757.     CrossRef
  • Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia
    Konstantinos Prokopidis, Stefano Cacciatore, Stephen D. Anton, John A. Batsis
    Advances in Therapy.2026;[Epub]     CrossRef
  • GLP-1 Receptor Agonists and Reproductive Health
    Florence Porterfield, Jennifer Mulligan, Katherine Salim, Olayemi Olubowale, Fatima Cody Stanford
    Endocrinology and Metabolism Clinics of North America.2026; 55(4): 637.     CrossRef
  • Anti-Obesity Effects of Artocarpus integer Stem Bark Extract via Appetite and Lipid Metabolism Modulation in Obese Rats
    Anton Bahtiar, Sekar Ayu Rabbani, Asfareni Rahmah, Sirithon Siriamornpun
    Applied Biosciences.2026; 5(3): 79.     CrossRef
  • Transcriptome profiling of human hypothalamic agouti-related protein and proopiomelanocortin neurons regulating energy homeostasis
    Szabolcs Takács, Katalin Skrapits, Balázs Göcz, Éva Rumpler, Miklós Sárvári, Barbara Göblyös, Dalma Biri, Szilárd Póliska, Gergely Rácz, András Matolcsy, Erik Hrabovszky
    Nature Communications.2026;[Epub]     CrossRef
  • Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials
    Elsayed S. Moubarak, Mohamed S. Elgendy, Omar Elkoumi, Ahmed A. Ibrahim, AlMothana Manasrah, Jamal Ahmad, Malak A. Hassan, Omar ElSayed Rageh, Abdelrahman Aly Mohamed, Amr Elzahaby, Mohamed Abuelazm
    Journal of Psychopharmacology.2026; 40(10): 1537.     CrossRef
  • Assessing the quality and reliability of health information on GLP-1 receptor agonists on TikTok and Bilibili: a cross-sectional analysis of the public health infodemic
    Gang Peng, Chen Wang, Hong-Wei Zhang, Ting Xu, Jian-Zhong Di
    Therapeutic Advances in Endocrinology and Metabolism.2026;[Epub]     CrossRef
  • Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
    Ji Yoon Kim, Nam Hoon Kim
    Diabetes & Metabolism Journal.2026; 50(5): 844.     CrossRef
  • Hypothalamic Inflammaging: A Central Driver of Type 2 Diabetes Mellitus and Metabolic Disease in Aging
    Sang Hee Lyoo, Ki Hun Kim, Ki Woo Kim
    Diabetes & Metabolism Journal.2026; 50(5): 863.     CrossRef
  • Neuroendocrine regulation of appetite and energy balance in metabolic disorders
    Mst. Mohona Khatun, Md. Nazmul Ahsan Sarker, Mohammad Shahangir Biswas, Munna Kumar Podder, Sabrina Akter
    IBRO Neuroscience Reports.2026; 21: 911.     CrossRef
  • The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
    Ghinwa M. Barakat, Samer El Hajj Hassan, Hussein Issa, Wiam Ramadan
    Current Drug Therapy.2026; 21(5): 660.     CrossRef
  • Beyond Weight Loss: Tolerability, Acceptability, and Patient-Centered Outcomes of GLP-1 Receptor Agonists in Polycystic Ovary Syndrome
    Urvah Tauseef, Farshi Farook, Vaishnavi J. Shetty, Edith Ramos-Ocola, Chandra Rupini Premkumar, Muhammad Zaryab Haider, Aashna Gandhi, Tunisha Shingala, Simardeep Singh, Muhammad Moiz Tahir, Sancia Mary Jerold Wilson, Kaaviyashri Saraboji, Jyoti Yadav, An
    Reproductive Medicine.2026; 7(4): 55.     CrossRef
  • Efsubaglutide Alfa: A Comprehensive Pharmacological Review
    Haolin Zheng, Run Yan, Fan Jiang, Yi Li, Gerald J. Prud’homme, Qinghua Wang
    Clinical Pharmacokinetics.2026;[Epub]     CrossRef
  • Efficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials
    Rida Wajid, Ravi Kumar, Misbah Muneer, Maria Nauroz Ali, Jazia Ul Mustafa, Javeria Qamar, Daniyal Asif, Saadia Ziaulhaque, Iqra Sohail, Fawaz Ahmed Khamisani, Maria Noureen, Sadaf Fatima, Ali Saqlain, Laksh Kumar, Adarsh Raja
    Journal of Diabetes & Metabolic Disorders.2026;[Epub]     CrossRef
  • Computational identification of potential GLP-1 receptor agonists from marine natural products for nutraceutical applications in diabetes and obesity management
    Fatemeh Hajipour, Omid Tavakkol Hamedani, Alireza Foroumadi, Nieves Gonzalez Gomez, Oscar Lorenzo Gonzalez, Loghman Firoozpour
    Results in Chemistry.2026; 32: 104042.     CrossRef
  • Hijacked Brain in Modern Obesity: Cue, Habit, Addiction, Emotion, and Restraint as Targets for Personalized Digital Therapy and Electroceuticals
    Taesung Lee, Seeun Park, Seokhyun Lee, Areum Hwangbo, HanGyeol Bae, Yumin Lee, Hyung Jin Choi
    Journal of Obesity & Metabolic Syndrome.2025; 34(3): 196.     CrossRef
  • Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis
    Zixuan Li, Zhoubo Han, Rong Sun, Xiuping Xuan, Chenghu Huang
    Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 3611.     CrossRef
  • The LEPR gene: A multifaceted regulator of energy homeostasis, obesity pathogenesis, and metabolic health
    Isar Sharma, Nishutosh, Kritika Bakshi, Ritu Mahajan, Nisha Kapoor
    Human Gene.2025; 46: 201486.     CrossRef
  • Glucagon-Like Peptide-1 Receptor Agonists Are Promising for the Treatment of Brain Diseases: an Outlook from the Perspective of Integrative Physiology
    N. V. Gulyaeva
    Journal of Evolutionary Biochemistry and Physiology.2025; 61(5): 1326.     CrossRef
  • Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes
    Isabel Krug, An Binh Dang, Jade Portingale, Yakun Li, Ying Qing Won
    Nutrients.2025; 17(23): 3735.     CrossRef
  • A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
    E. A. Troshina, M. B. Antsiferov, A. S. Ametov, G. R. Galstyan, T. N. Markova, T. I. Romantsova, N. V. Mazurina, O. M. Koteshkova
    Problems of Endocrinology.2025; 71(5): 19.     CrossRef
Original Articles
Pharmacotherapy
Article image
Initial Pharmacological Strategies in People with Early Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis
Jong Han Choi, Bo Kyung Koo, Ye Seul Yang, Se Hee Min, Jong Suk Park, Sang Youl Rhee, Hyun Jung Kim, Min Kyong Moon
Diabetes Metab J. 2025;49(6):1252-1261.   Published online April 29, 2025
DOI: https://doi.org/10.4093/dmj.2024.0660
  • 13,177 View
  • 576 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Type 2 diabetes mellitus (T2DM) requires stringent glycemic control from an early stage to prevent complications. The most effective treatment regimen for early T2DM remains unclear. The study aimed to compare the efficacy and safety of monotherapies and combination therapies for early T2DM.
Methods
A systematic review and network meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Randomized controlled trials focused on glycemic control, body weight, and adverse events were included. The primary outcomes were changes in glycosylated hemoglobin (HbA1c) and odds of achieving the target HbA1c after 6 months.
Results
All combination therapies were more effective than monotherapy. Metformin+glucagon-like peptide-1 receptor agonists (GLP-1RA) (weighted mean difference [WMD] –1.50%; 95% confidence interval [CI] –2.04 to –0.96) and metformin+dipeptidyl peptidase-4 inhibitors (WMD –1.46%; 95% CI, –1.96 to –0.95) were the most effective for change in HbA1c. GLP-1RA and sodium- glucose cotransporter-2 inhibitors led to weight reduction. Apart from the increased risk of hypoglycemia with sulfonylureas, no significant differences in adverse events were observed across regimens.
Conclusion
Early combination therapy effectively improved glycemic control in patients with early T2DM without significantly increasing adverse risks. Future studies should explore new combinations, including potent GLP-1RA.

Citations

Citations to this article as recorded by  
  • LASSBio-1986 as a Multifunctional Antidiabetic Lead: SGLT1/2 Docking, Redox–Inflammatory Modulation and Metabolic Benefits in C57BL/6 Mice
    Landerson Lopes Pereira, Raimundo Rigoberto B. Xavier Filho, Gabriela Araújo Freire, Caio Bruno Rodrigues Martins, Maurício Gabriel Barros Perote, Cibelly Loryn Martins Campos, Manuel Carlos Serrazul Monteiro, Isabelle de Fátima Vieira Camelo Maia, Renata
    International Journal of Molecular Sciences.2026; 27(2): 829.     CrossRef
  • Metformin beyond Glycemic Control: New Mechanistic Insights and Expanding Therapeutic Horizons
    Eugene Han, Jung Ho Nam, Insuk Lee, Cheol Ryong Ku, Yong-ho Lee
    Diabetes & Metabolism Journal.2026; 50(3): 435.     CrossRef
  • Early combination therapy in type 2 diabetes: Rethinking initial treatment strategies
    Andrej Janez, Tanja Smid, Manfredi Rizzo, Tsvetalina Tankova
    Journal of Diabetes and its Complications.2026; 40(10): 109392.     CrossRef
  • Adverse event reporting signals for SGLT-2 inhibitor–metformin combination therapy: a disproportionality analysis of the FAERS database
    Wei Zhou, Yimiao Xia, Jing Li, Facai Wang
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
Others
Article image
Fibroblast Growth Factor 21 Levels Are Associated With Perception and Neural Responses to Sweetness in Type 2 Diabetes Mellitus
Piao Kang, Ying Zhang, Dian Zeng, Dan Liu, Rui Han, Yuwei Lu, Di Cheng, Qinyi Wang, Silin Liu, Liang Wu, Qian Wu, Shujie Yu, Anran Chen, Jingyi Guo, Wenli Ge, Jiacheng Ni, Jingyi Yang, Xiaomeng Wu, Lifei Ma, Weiping Jia, Qichen Fang, Yuehua Li, Huating Li
Diabetes Metab J. 2025;49(4):893-905.   Published online March 26, 2025
DOI: https://doi.org/10.4093/dmj.2024.0390
  • 8,930 View
  • 144 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The relationship between fibroblast growth factor 21 (FGF21) and sweet taste perception and preference in type 2 diabetes mellitus (T2DM) remains unclear. This study aims to investigate this relationship and examine the neural responses of T2DM patients to high-calorie sweet (HCS) food pictures, further exploring its correlation with FGF21 levels.
Methods
We assessed sweet taste perception and preference in 40 T2DM patients and 41 controls using classical scales. Subsequently, the neural responses of 11 T2DM patients and 11 controls to HCS pictures were examined using functional magnetic resonance imaging. FGF21 levels were measured using chemiluminescent immunoassay, and the correlations with taste perception and neural responses were analyzed.
Results
Increased FGF21 levels were associated with decreased sweet perception and increased sweet taste preference in T2DM patients. Compared to control, T2DM patients exhibited greater neural activations in the orbitofrontal cortex, anterior cingulate cortex (ACC), thalamus, and hippocampus (HCS vs. non-food) as well as the putamen (HCS vs. low-calorie food). Notable differences were observed in the parahippocampal gyrus, insula, ACC, and hippocampus in T2DM patients (HCS vs. high-calorie non-sweet). Additionally, FGF21 accounted for 30.39% and 32.4% of the associations between T2DM and ACC, and parahippocampal gyrus, respectively.
Conclusion
FGF21 levels were independently associated with changes in sweet taste perception and preference in T2DM patients and were significantly associated with activation in reward-related brain regions. This study reveals the potential role of FGF21 in regulating responses to sweet foods in T2DM and provides insight to develop new therapeutic strategies for diabetes.

Citations

Citations to this article as recorded by  
  • Exploring Biomarkers in Type 2 Diabetes Mellitus versus Normoglycemia Identified through High-Throughput Proteomics: A Systematic Review and Meta-Analysis
    Julia García-Currás, Raquel Pérez-Lois, Guillermo L. Taboada, María P. Pata
    Journal of Proteome Research.2026; 25(1): 4.     CrossRef
  • Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential
    Mariam Alamgir, Aalam Sohal, Kris Kowdley
    Drug Design, Development and Therapy.2026; Volume 20: 1.     CrossRef
Complications
Article image
Global, Regional, and National Temporal Trends in Incidence for Type 2 Diabetes Mellitus Related Chronic Kidney Disease from 1992 to 2021
Yu Cao, Huiting Chen, Hui Liu, Hao Wu, Wei Gao
Diabetes Metab J. 2025;49(4):848-861.   Published online March 11, 2025
DOI: https://doi.org/10.4093/dmj.2024.0593
  • 13,252 View
  • 260 Download
  • 15 Web of Science
  • 16 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Type 2 diabetes mellitus (T2DM) is a major cause of declining renal function.
Methods
Temporal trends in T2DM-related chronic kidney disease (CKD-T2DM) incidence across 204 countries and territories from 1992 to 2021 were analyzed using data from the Global Burden of Disease 2021. The impact of macro-factors (demographic change, age, period, and birth cohort) on CKD-T2DM incidence trends was assessed using decomposition analyses and age-period- cohort modeling, highlighting opportunities to improve incidence and reduce regional disparities.
Results
In 2021, global CKD-T2DM incidence cases reached 2.01 million, a 150.92% increase since 1992, with population growth and aging contributing to 80% of this rise. The age-standardized incidence rate (ASIR) ranged from 15.09 per 100,000 in low sociodemographic index (SDI) regions to 23.07 in high SDI regions. China, India, the United States, and Japan have the most incidence cases, accounted for 69% of incidence cases globally. With 175 countries showing an increasing ASIR trend. Unfavorable trend in ASIR increase were generally found in most high-middle and middle SDI countries, such as China and Mexico (net drift=0.15% and 1.17%, per year). Age-period-cohort analyses indicated a high incidence risk near age 80, with worsening risks for recent periods and birth cohorts, except in high SDI areas.
Conclusion
The CKD-T2DM incidence burden continues to rise globally, with significant variations between countries, posing major global health implications. CKD-T2DM is largely preventable and treatable, warranting greater attention in global health policy, particularly for older populations and in low and middle SDI regions.

Citations

Citations to this article as recorded by  
  • Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease: challenges and opportunities
    Jean-Michel Halimi, Laurent Fauchier, Alexandre Karras, Chloé Amouyal, Dominique Eladari, Patrick Rossignol, Gabriel Choukroun, Philippe Zaoui, Nicolas Girerd, Samy Hadjadj
    European Journal of Preventive Cardiology.2026; 33(1): 8.     CrossRef
  • Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis
    Xiaojian Zhu, Xingjia Wang, Peiru Zhang, Zhuoshi Yang, Na Zhao, Jiameng Li, Yunze Shi, Yichen Zhao, Jian Ma
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • 2026 Latin American consensus for the management of patients with hypertension and cardio-renal and metabolic disturbances: endorsed by the Latin American Society of Hypertension, the Iberoamerican Hypertension League, and the World Hypertension League
    Antonio Coca, Ramiro Sánchez, Dora I. Molina de Salazar, Ernesto Peñaherrera, Luis Alcocer, Eduardo Barbosa, Guido Grassi, Patricio Lopez-Jaramillo, Empar Lurbe, José Parra-Carrillo, Agustín J. Ramirez, Josep Redón, Weimar Sebba-Barroso, Andrés Acosta, Da
    Journal of Hypertension.2026; 44(6): 885.     CrossRef
  • Diabetic kidney disease: Radiological assessment and clinical correlations
    Salvatore Silipigni, Guido Gembillo, Lorenzo Lo Cicero, Serena Ausilia Ferrara, Maria Federica Ricca, Giuseppe Spadaro, Luca Soraci, Antonio Bottari
    World Journal of Diabetes.2026;[Epub]     CrossRef
  • Global burden of chronic kidney disease due to type 2 diabetes in adults from 1990 to 2021, with exploratory projections to 2036: a systematic analysis of the Global Burden of Disease Study 2021
    Yazhi Wang, Hui Chen
    Diabetes Research and Clinical Practice.2026; 237: 113340.     CrossRef
  • Burden and trends of chronic kidney disease due to type 2 diabetes mellitus in China and G20 countries, 1990–2023: a comparative analysis
    Jincheng Li, Xinyu Li, Hongtao Zhao, Xinyu Yang, Yulin Li
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Prognostic value of the atherogenic index of plasma for early-stage diabetic kidney disease in type 2 diabetes: a retrospective cohort study using supervised machine learning
    Yazhi Wang, Hui Chen
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Silymarin attenuates diabetic nephropathy in rats via modulation of the miRNA-223/NLRP3/caspase-1/GSDMD axis and inflammasome-related pyroptotic signaling
    Merna G. Aboismaiel, Mohamed N. Amin, Laila A. Eissa
    Biology Direct.2026;[Epub]     CrossRef
  • Global burden and future trends of type 2 diabetes mellitus-associated chronic kidney disease: analysis of the Global Burden of Disease Study 2021
    Naitao Shen, Shanshan Jin, Zhongyu Yue, Zhujin Song, Miaolian Wu
    International Journal of Clinical Pharmacy.2026; 48(6): 2226.     CrossRef
  • Nicotinamide mononucleotide alleviates the streptozotocin-mediated ferroptosis of islet β-cells via the Nrf2/GPX4 pathway
    Decheng Lu, Jianli Huang, Jinyue Meng, Jiayu Luo, Xuemei Huang
    Brazilian Journal of Medical and Biological Research.2026;[Epub]     CrossRef
  • Hypothalamic Inflammaging: A Central Driver of Type 2 Diabetes Mellitus and Metabolic Disease in Aging
    Sang Hee Lyoo, Ki Hun Kim, Ki Woo Kim
    Diabetes & Metabolism Journal.2026; 50(5): 863.     CrossRef
  • Global transitions of concomitant patterns and risk factors of cardio-renal-metabolic conditions among the elderly
    Shuzhen Zhao, Chengnan Guo, Xin Zhang, Yi Li, Jingkun Hu, Jiayi Huang, Luojia Dai, Zhenqiu Liu, Tiejun Zhang, Lewis A Lipsitz
    The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences.2026;[Epub]     CrossRef
  • Frailty and incident diabetes among middle-aged and older adults: Evidence from a large prospective cohort in China
    Yingzhen Gu, Xiaorong Han, Jinxing Liu, Yifan Li, Wei Zhang, Naqiang Lv, Aimin Dang
    Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(10): 104114.     CrossRef
  • Addressing Inequities in Early‐Onset Diabetic Kidney Failure in Australia: A Response to Ellis et al.
    Gokhan Koker
    Nephrology.2025;[Epub]     CrossRef
  • An Overview of Sex-Based Differences in the Onset and Progression of DKD in the Well-Known Model, ZSF1 Rats
    Arunita Chatterjee, Sharma S. Prabhakar
    Life.2025; 15(10): 1627.     CrossRef
  • Electroacupuncture ameliorates glycolipid metabolism disorder in skeletal muscle of type 2 diabetic rats via modulation of the AMPK/PGC-1α/TFAM signaling pathway
    Fang Luo, Junjie Feng, Jumahan Nverjiang, Jiangnan Ye, Chang Liu, Hanhan Chen, Zhuoxuan Li, Qunwen Lu, Wei Zhang, Furong Zhang, Jun Zhu, Chengguo Su
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
Guideline/Statement/Fact Sheet
Article image
Prevalence, Incidence, and Metabolic Characteristics of Young Adults with Type 2 Diabetes Mellitus in South Korea (2010–2020)
Ji Yoon Kim, Jiyoon Lee, Joon Ho Moon, Se Eun Park, Seung-Hyun Ko, Sung Hee Choi, Nam Hoon Kim
Diabetes Metab J. 2025;49(2):172-182.   Published online March 1, 2025
DOI: https://doi.org/10.4093/dmj.2024.0826
  • 14,211 View
  • 527 Download
  • 23 Web of Science
  • 26 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study aimed to examine trends in the prevalence, incidence, metabolic characteristics, and management of type 2 diabetes mellitus (T2DM) among young adults in South Korea.
Methods
Young adults with T2DM were defined as individuals aged 19 to 39 years who met the diagnostic criteria for T2DM. Data from the Korean National Health Insurance Service-Customized Database (2010–2020, n=225,497–372,726) were analyzed to evaluate trends in T2DM prevalence, incidence, metabolic profiles, comorbidities, and antidiabetic drug prescription. Additional analyses were performed using the Korea National Health and Nutrition Examination Survey.
Results
The prevalence of T2DM in young adults significantly increased from 1.02% in 2010 to 2.02% in 2020 (P<0.001), corresponding to 372,726 patients in 2020. Over the same period, the incidence rate remained stable within the range of 0.36% to 0.45%. Prediabetes prevalence steadily increased from 15.53% to 20.92%, affecting 3.87 million individuals in 2020. The proportion of young adults with T2DM who were obese also increased, with 67.8% having a body mass index (BMI) ≥25 kg/m² and 31.6% having a BMI ≥30 kg/m² in 2020. The prevalence of hypertension, dyslipidemia, and fatty liver disease also increased, reaching 34.2%, 79.8%, and 78.9%, respectively, in 2020. Although the overall pharmacological treatment rate remained low, the prescription of antidiabetic medications with weight-reducing properties increased over the study period.
Conclusion
The prevalence of T2DM among young adults in South Korea nearly doubled over the past decade. The strong association with obesity and metabolic comorbidities emphasizes the urgent need for targeted prevention and management strategies tailored to this population.

Citations

Citations to this article as recorded by  
  • Association between body weight time in target range and risk of type 2 diabetes in adults with obesity
    Soojin Park, Seohyun Kim, Sang Ho Park, Minkyeong Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Gyuri Kim
    Diabetology & Metabolic Syndrome.2026;[Epub]     CrossRef
  • Diabetes Fact Sheet 2025: Comparative Epidemiology and Clinical Features of Obese and Non-Obese Diabetes in Korea
    Jin Hwa Kim, Bongseong Kim, Se Eun Park, Seung-Hyun Ko, Sung Hee Choi, Bong Soo Cha, Kyungdo Han, Seung-Hwan Lee
    Diabetes & Metabolism Journal.2026; 50(2): 267.     CrossRef
  • Diabetes Fact Sheet 2025: Special Edition on Diabetes with Obesity and in Pregnancy
    Se Eun Park, Se Hee Min, Jin Hwa Kim, Seung-Hwan Lee, Han Na Jung, Joon Ho Moon, Kyungdo Han, Seung-Hyun Ko, Bong Soo Cha, Sung Hee Choi
    Diabetes & Metabolism Journal.2026; 50(2): 255.     CrossRef
  • Temporal trends in macrovascular complications in young-onset diabetes in Korea: A nationwide population-based study
    Hwa Young Kim, Eunjeong Ji, Jaehyun Kim
    Diabetes Research and Clinical Practice.2026; 236: 113285.     CrossRef
  • Association between relative handgrip strength and glycemic control among male automobile manufacturing workers using vibration tools in South Korea
    Dong-Jae Seo, Hyun Joong Kim, Yongjin Kim, Jaewon Mun, Jong-Han Leem, Shin-Goo Park, Dong-Wook Lee, Hwan-Cheol Kim
    Annals of Occupational and Environmental Medicine.2026; 38: e14.     CrossRef
  • Hypertriglyceridemia in adults with diabetes mellitus in Korea: Sex, age, and lifestyle determinants
    Kye-Yeung Park, Sangmo Hong, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
    Journal of Clinical Lipidology.2026; 20(7): 1377.     CrossRef
  • Remission in Young-Onset Type 2 Diabetes: Mechanisms, Intervention Strategies, and Predictive Factors
    易宏 邹
    Advances in Clinical Medicine.2026; 16(05): 301.     CrossRef
  • Sex-stratified associations of TyG index and HOMA-IR changes with incident type 2 diabetes
    Sojin Kim, Sujeong Shin, Yoosoo Chang, Eunju Sung, Jae-Heon Kang
    Scientific Reports.2026;[Epub]     CrossRef
  • Circulating GDF15 levels reflect metabolic and inflammatory burden in early dysglycemia: findings from the ADIOS cohort
    Ji Yoon Kim, Ah Hyeon Lee, Jiyoon Lee, Hye-Min Jang, Sin Gon Kim, Dong-Hoon Kim, Nam Hoon Kim
    Diabetes Research and Clinical Practice.2026; 239: 113461.     CrossRef
  • Vegetable‐First Meal Sequence Suppresses Postprandial Glycaemic Excursions and Variability in Young Women With High‐Risk Phenotype for Early‐Onset Type 2 Diabetes: A 4‐Arm Randomized Crossover Trial With Continuous Glucose Monitoring
    Minji Choi, Soyoon Lee, Eujean Bang, Ijae Seo, Jieun Lee, Sehyun Joo, Hyeonseo Kim, Song Vogue Ahn, Yuri Kim, Jieun Oh
    Diabetes, Obesity and Metabolism.2026; 28(11): 10218.     CrossRef
  • Machine learning models for predicting new-onset diabetes following acute pancreatitis using real-world data
    Djibril M Ba, Alireza Vafaei Sadr, Yue Zhang, Phil A. Hart, Nazia Raja-Khan, Ruizhe Zhou, Ayesha Siddiqui, Tian Qiu, Jennifer Maranki, Vernon M. Chinchilli, Vida Abedi
    BMJ Public Health.2026; 4(3): e004661.     CrossRef
  • Physical activity and type 2 diabetes risk
    Jing Liu, Qingtao Zeng
    Medicine.2026; 105(36): e50570.     CrossRef
  • Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
    Ji Yoon Kim, Nam Hoon Kim
    Diabetes & Metabolism Journal.2026; 50(5): 844.     CrossRef
  • Pre-Post Changes in Gut Health and Metabolic Risk Indicators After a Workplace Partially Hydrolyzed Guar Gum (Sunfiber®) Dietary Fiber Intervention Program: An Open-Label Single-Arm Study
    Yu Na Song, Hyoung Su Park, Hana Jang, Hye-Jin Kim
    Korean Journal of Human Ecology.2026; 35(4): 709.     CrossRef
  • Predictive value of glycated hemoglobin levels for large for gestational age infants in women with pregestational diabetes according to body mass index
    Sujin Lee, Suyeon Park, Ji-Hee Sung, Hyun-Joo Seol, JoonHo Lee, Seung-Chul Kim, Sae-Kyoung Choi, Seung Mi Lee, Se Jin Lee, Han-Sung Hwang, Gi-Su Lee, Hyun-Soo Park, Soo-Jeong Lee, Geum Joon Cho, Subeen Hong, Hyun Sun Ko
    Obstetrics & Gynecology Science.2026; 69(5): 305.     CrossRef
  • Effects of ultra-processed food reduction intervention on postprandial glucose and glycaemic variability in Korean young adults: study protocol for the ULTRA-CGM randomised controlled trial
    Yujin Kim, Dabin Jeong, Jiyoon Lee, Sooran Yang, Megan S Rojas Guzman, Jihoon You, Jeongsoo Lim, Sujin Lee, Hannah Oh
    BMJ Open.2026; 16(10): e120830.     CrossRef
  • Trends and Disparities in Diabetes Prevalence in Ontario, Canada Between 2015 and 2021
    Christina Hanna, Deva Thiruchelvam, Chris Kenaszchuk, Lorraine L. Lipscombe, Baiju R. Shah, Calvin Ke, Gillian L. Booth, Laura C. Rosella, Fatema M. Ali, Aimen Zehra, Ghazal S. Fazli
    Canadian Journal of Diabetes.2026;[Epub]     CrossRef
  • Prediabetes subtype-based stratification reveals distinct long-term risks for type 2 diabetes
    Hun Jee Choe, Wonsuk Choi, Howard H. Chang, Dimple Kondal, K. M. Venkat Narayan, Joon Ho Moon, Nam H. Cho
    Diabetologia.2026;[Epub]     CrossRef
  • Rationale and design of a nationwide prospective cohort study in type 2 diabetic kidney disease: the Korean Diabetic Kidney Disease (K-DKD) Cohort
    Jin Joo Cha, Dae Ryong Cha, Yaeni Kim, Cheol Whee Park, Hyung Duk Kim, Ju-Young Moon, Kyubok Jin, Sang Heon Song, Jung-Hwan Lee, Samel Park, Eun Young Lee, Tae-Hyun Yoo, Won Kim, So Young Lee, Jwa-Kyung Kim, Seung Seok Han, Mi-Yeon Yu, Sang Youb Han
    Kidney Research and Clinical Practice.2026; 45(6): 1045.     CrossRef
  • Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality
    Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park
    Cardiovascular Diabetology.2025;[Epub]     CrossRef
  • Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study
    Ji Yoon Kim, Nam Hoon Kim, Jiyoon Lee, Dong-Hoon Kim, Sin Gon Kim
    European Heart Journal - Cardiovascular Pharmacotherapy.2025; 11(7): 620.     CrossRef
  • Young Adults at Risk: Tackling the Surge of Early‑Onset Type 2 Diabetes in Korea
    Eun-Hee Cho
    Endocrinology and Metabolism.2025; 40(4): 542.     CrossRef
  • Young patients with type 2 diabetes have high relative risks for complications in a country with middle-high sociodemographic index, similarly to those countries with high index
    Gergő A. Molnár, Zoltán Kiss, István Wittmann
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Cost-Effectiveness Analysis of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in People With Type 2 Diabetes Treated With Non-Intensive Insulin Therapy in South Korea
    Ji Yoon Kim, Sabrina Ilham, Hamza Alshannaq, Richard F. Pollock, Martin Field, Gregory J. Norman, Sang-Man Jin, Jae Hyeon Kim
    Journal of Diabetes Science and Technology.2025;[Epub]     CrossRef
  • Can screening for albuminuria detect type 2 diabetes mellitus?
    Mi Kyung Kim
    Kidney Research and Clinical Practice.2025; 44(6): 857.     CrossRef
  • Association between severe acute pancreatitis and new-onset diabetes: a propensity score-matched real-world study
    Djibril M. Ba, Phil A. Hart, Tian Qiu, Somashekar G. Krishna, Xiang Gao, Douglas L. Leslie, David Bradley, Jennifer Maranki, Kadiyatu Fofana, Vernon M. Chinchilli, Ariana R. Pichardo-Lowden
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
Metabolic Risk/Epidemiology
Article image
Effects of Pancreatitis and Type 2 Diabetes Mellitus on the Development of Pancreatic Cancer: A Nationwide Nested Case-Control Study
Young-eun Kim, Min Heui Yu, Chung Mo Nam, Eun Seok Kang
Diabetes Metab J. 2025;49(2):252-263.   Published online March 1, 2025
DOI: https://doi.org/10.4093/dmj.2024.0277
  • 11,028 View
  • 291 Download
  • 4 Web of Science
  • 5 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Despite diabetes mellitus (DM) and pancreatitis being known risk factors for pancreatic cancer, patients with these conditions are not included in pancreatic cancer screening due to the low incidence of pancreatic cancer in these populations. This study aimed to determine the high-risk subgroup of patients with diabetes and pancreatitis that would benefit from pancreatic cancer screening.
Methods
A nested case-control study was conducted using data from the National Health Information Database of the Korean National Health Insurance Service. Patients were categorized into the following groups: type 2 diabetes mellitus only (T2DM-only), pancreatitis-only (PAN-only), T2DM followed by pancreatitis (T2DM-PAN), post-pancreatitis diabetes mellitus (PPDM), and no diabetes and no pancreatitis (NDNP). Conditional logistic regression was used to determine significant associations of each group with pancreatic cancer development risk.
Results
The risk of pancreatic cancer was significantly higher in the T2DM-PAN (adjusted odds ratio [AOR], 4.96; 95% confidence interval [CI], 4.48 to 5.49) and PPDM (AOR, 4.71; 95% CI, 4.12 to 5.37) groups than in the NDNP group. Compared to patients in the NDNP group, those with PPDM using insulin had a 17-fold increased risk (AOR, 16.72; 95% CI, 9.50 to 29.43), and individuals with PPDM who had diabetes for less than 3 years had a more than 8-fold increased risk of pancreatic cancer (AOR, 8.83; 95% CI, 5.99 to 13.01).
Conclusion
In patients with post-pancreatitis diabetes, insulin use or shorter duration of diabetes was associated with a higher risk of pancreatic cancer, suggesting that patients in these subgroups may require close monitoring for pancreatic cancer development.

Citations

Citations to this article as recorded by  
  • Nationwide Big Data Studies of Endocrine Diseases Using the Korean National Health Information Database: Research Trends and Standardization of Operational Definitions
    Sun Wook Cho, Jung Hee Kim, Kyoung Jin Kim, Beom-Jun Kim, Mee Kyoung Kim, Eun Jung Rhee
    Endocrinology and Metabolism.2026; 41(1): 86.     CrossRef
  • Pancreatic Cancer Risk in Glycemically Defined New-Onset Diabetes
    Hans Scherübl
    Gastroenterology.2026; 170(7): 1630.     CrossRef
  • Pancreatic cancer risk in people 60 or over with new-onset diabetes and weight loss or pancreatitis
    Hans Scherübl
    Pancreatology.2026;[Epub]     CrossRef
  • Effects of Pancreatitis and Type 2 Diabetes Mellitus on the Development of Pancreatic Cancer: A Nationwide Nested Case-Control Study (Diabetes Metab J 2025;49:252-63)
    Young-eun Kim, Min Heui Yu, Chung Mo Nam, Eun Seok Kang
    Diabetes & Metabolism Journal.2025; 49(3): 522.     CrossRef
  • Pancreatitis, Type 2 Diabetes Mellitus, and Pancreatic Cancer (Diabetes Metab J 2025;49:252-63)
    Shih-Wei Lai, Kuan-Fu Liao
    Diabetes & Metabolism Journal.2025; 49(3): 518.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP